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Abstract 
Apurinic/apyriraidinic endonuclease 1 (APE1) is a multi-functional mammalian protein 
which has recently been shown to possess the ability to endonucleolytically cleave single-
stranded RNA and abasic RNA. Several population variants of APE1 (L104R, E126D and 
D148E) are known to exist in the human population. L104R and E126D have been linked to 
Amyotrophic Lateral Sclerosis while D148E has been linked to various cancers. The exact 
molecular mechanisms which correlate these variants with human diseases are currently 
unknown. Recent evidence has shown that the in vitro endoribonuclease activities of these 
variants are different from the wild-type APE1 protein. Here, we hypothesize that the altered 
endoribonuclease activity of APE1 population variants may be associated with phenotype 
changes leading to disease pathogenesis. The goal of this thesis was to determine whether APE1 
population variants can cause an altered phenotype when expressed in prokaryotic (Origami™ 
(DE3) cells) and eukaryotic systems (HeLa cervical cancer and HepG2 hepatoma cancer cell 
lines). Subsequently, these changes were to be linked to altered endoribonuclease activity of 
these variants. 
Using two separate assays, it was shown that the L104R and E126D variants possess 
enhanced cytotoxicity to Origami™ (DE3) cells. This correlates with their distinct 
endoribonuclease activity demonstrated in vitro. The D148E variant, which had lost 
endoribonuclease activity, had no effect on colony formation and growth of Origami™ (DE3) 
cells. Interestingly, this study also showed that, when over-expressed, the L104R and E126D 
variants are capable of causing enhanced growth in the mammalian HepG2 cells. Preliminary 
microarray and quantitative real time polymerase chain reaction experiments were conducted in 
an attempt to understand the mechanism for the L104R-induced cell growth in HepG2 cells. 
Unfortunately, the results were inconclusive. In summary, this thesis has demonstrated a solid 
correlation between having distinct endoribonuclease activity and the ability to influence cell 
growth in prokaryotic and eukaryotic cells such as shown for the L104R and E126D APE1 
population variants. Such observations provide a framework for future investigations into 
determining how changes in endoribonuclease activity may be linked to human diseases. 
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CHAPTER 1 - INTRODUCTION 
Chapter 1 
Introduction 
In 2009, the Human Apurinic/Apyrimidinic endonuclease 1 (APE1) protein was 
identified as an endoribonuclease capable of regulating c-myc messenger (mRNA) levels in 
eukaryotic cells. The regulation of mRNA stability is a complex process and is based on many 
cis-regulatory elements and trans- acting factors. mRNA stability is recognized as a major point 
in the regulation of gene expression. Deregulation of the process can lead to disease in 
eukaryotic organisms. As such, APE1 maybe implicated in mammalian diseases. In addition, 
APE1 genes are known to exist as various single nucleotide polymorphisms (SNPs) in the human 
population. This can result in amino acid substitutions and the subsequent expression of the 
human population variants of the APE1 protein. Preliminary studies indicate both possible 
alterations in mRNA cleavage activity for these variants and correlations between expression of 
these variants of APE1 and disease. Thus, the primary focus of this thesis is to examine if the 
expression of these population variants results in altered phenotype as compared to the wild-type 
APE1 for both prokaryotic and eukaryotic systems. This may indicate a role in possible 
downstream disease pathogenesis. If these effects are observed, further investigations into the 
possible molecular mechanism for these altered phenotypes can be pursued. 
1.1 Eukaryotic Gene expression and mRNA decay 
The regulation of gene expression is a highly complex process which occurs at many 
levels including transcriptional, post-transcriptional, translational and post-translational (Parker 
et al. 2004). At the post-transcriptional level, one mechanism has been recently identified as a 
1 
CHAPTER 1 - INTRODUCTION 
key control point in gene expression: the regulation of mRNA stability. The mechanism is also 
sometimes known as mRNA turnover or degradation (Garneau et al. 2007). mRNA stability is a 
term which describes the factors and processes which are involved in the regulation of the half-
life of mRNA molecules. The following is a brief description of the importance of mRNA 
stability in gene expression and the key players involved in the control of mRNA stability. 
1.1.1 Significance of mRNA stability in the Control of Gene Expression 
The regulation of mRNA stability and degradation has been identified to be present in 
nearly all organisms (Nicholson et al. 1999; Gutierrez et al. 1999; Mello et al. 2004). 
Degradation will have a direct effect on the stability of a particular species of mRNA in a cell 
and will determine the levels of mRNA for that particular gene. The alteration in mRNA levels 
can result in changes in associated cellular protein levels and have consequent effects on that 
organism (Ross et al. 1995). The degradation of mRNA molecules has been investigated in more 
detail as evidence has been discovered which implies that mRNA degradation plays a vital role 
in gene expression. For example, mRNA degradation has been shown to be integral in post-
transcriptional gene silencing, also known as RNA-mediated interference. In RNA-mediated 
interference, specific mRNA molecules are targeted for degradation by complimentary RNA 
molecules and are subsequently degraded by cellular degradation machinery, resulting in 
lowered levels of expression of the targeted genes (Belostotsky et al. 2004). RNA-mediated 
interference has been identified as an anti-viral defense mechanism in eukaryotes (Mello et al. 
2004). Increased stability of an mRNA species can result in a longer half-life for the mRNA 
molecule with a subsequent increase in protein levels. For example, studies using cDNA arrays 
in activated T-cells and UV irradiated cells have clearly demonstrated an increase in mRNA 
levels for genes implicated in vital cellular processes such as the immune response (Raghavan et 
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al. 2002) and stress responses (Fan et al. 2002). Further evidence highlights this importance by 
indicating that mRNA turnover is vital in the proper development of eukaryotic organisms such 
as Drosophila melanogaster by regulating the proper chronological expression of developmental 
proteins (Thomsen et al. 2010). Deregulation of mRNA turnover is associated with the 
development of cancers, such as leukemia, by causing normal cells to acquire new protein 
expression profiles conducive to a cancerous phenotype (Audic et al. 2004, Steinman et al. 
2007). As such, mRNA stability and turnover are key control points in cellular function. 
1.1.2 General Overview of Factors involved in mRNA stability 
There are two known modes of mRNA decay in mammalian cells - either beginning from 
the ends of the mRNA transcript (exoribonucleolytic fashion) or from an internal site within the 
mRNA transcript (endoribonucleolytic fashion). Several factors are known to affect the 
regulation of mRNA stability and degradation. These factors can be categorized into two 
divisions - cw-regulatory elements, consisting of elements of the mRNA molecule itself, and 
trans acting factors, consisting of various protein factors and enzymes. Examples of cis-
regulatory elements include the 7' methylguanosine cap (m7G) and 3' poly adenosine tail which 
both confer a protective effect on mRNA molecules (Garneau et al. 2007). Both of these 
elements must be removed prior to degradation by the conventional exoribonucleolytic 
pathways, which degrade mRNA molecules from either the 5' or 3' ends. Examples of such 
trans acting factors are generally RNA-binding proteins and various types of enzymes. RNA-
binding proteins are proteins which bind to the mRNA molecule, either in the untranslated 
regions or in the protein coding region. These binding proteins can act to facilitate degradation 
of the mRNA molecule by recruiting enzymes involved in mRNA decay such as decapping 
enzymes and ribonucleases. RNA binding proteins can also act to increase the half-life of the 
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mRNA by blocking the effects of mRNA degrading machinery in the cell and thus subsequently 
increasing the mRNA levels. An example of this is the Coding Region Determinant-Binding 
Protein (CRD-BP) (Ioannidis et al. 2005). 
Another class of proteins involved in the degradation of mRNA are the decapping 
enzymes. These decapping enzymes are required for removal of the m7G cap present on mRNA 
molecules for 5' to 3' degradation of RNA. In mammals, the proteins involved in this process are 
the mRNA-decapping enzyme subunit 1 (Dcplp) and mRNA-decapping enzyme subunit 2 
(Dcp2p) proteins (Garneau et al. 2007). Similarly, removal of the 3' protective poly (A) tail can 
facilitate the degradation of mRNA molecules in an exoribonucleolytic fashion from the 3' end 
of the molecule. The proteins involved in this activity, in mammals, are the dual function 
proteins Poly A Ribonuclease (PARN) and Carbon Catabolite Repressor Protein 4 homolog B 
(CCR4b-NOT) (Garneau et al. 2007). 
The final class of enzymes which play a critical role in mRNA stability in cells are the 
ribonucleases. These enzymes are directly responsible for degradation of the mRNA molecule by 
hydrolytic cleavage. These can act either from the 5' or 3' ends of the mRNA molecule (referred 
to as exoribonucleases) or from an internal point in the mRNA molecule (referred to as 
endoribonucleases). Exoribonucleases are well studied in mammalian cells and were historically 
considered the primary enzymes responsible for the degradation of mRNA transcripts (Garneau 
et al. 2007). Exoribonucleases can be categorized into 6 superfamilies based on nucleic acid 
sequence and catalytic properties (Zuo et al. 2001). Specific examples of a 5' to 3' 
exoribonucleases are 5'-3' exoribonuclease 1 (XRN1) (Mitchell et al. 1997) and the exosome 
complex (Lebreton et al. 2008). A specific example of a 3' to 5' exoribonuclease is the 
previously mentioned PARN protein (Martinez et al. 2001). Endoribonucleases have been much 
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less studied in mammalian cells; however, evidence from the last decade suggests that 
endoribonucleases may play a more important role in gene expression than previously thought 
due to a potential increase in efficiency for mRNA cleavage unique to the mechanism of 
endoribonucleolytic cleavage. 
1.2 Eukaryotic Endoribonucleases 
Historically, the majority of mRNA decay was thought to be carried out in an 
exoribonucleolytic fashion in which the mRNA molecule is degraded from the 5' end, following 
decapping, or from the 3' end, following deadenylation (Houseley et al. 2009). However, the 
mechanism of function for endoribonucleases implies that they can bypass both decapping and 
deadenylation steps and can, in theory, be much more efficient than exoribonucleases. 
1.2.1 Significance of Endonucleolytic Cleavage 
In the past 5 years, there have been several studies on endoribonucleases which indicate 
that these enzymes play a more important role in mRNA degradation than previously thought. 
One example where endoribonuclease activity has been shown to be more important is the 
exosome. A component of the exosome, Exosome complex exonuclease DIS3 (Dis3/Rrp44), 
possesses endoribonuclease activity (Lebreton et al. 2008). The exosome is known to facilitate 
the degradation of many mammalian mRNAs and is a vital component of mRNA metabolism 
where, previously, it was thought Dis3/Rrp44 degraded mRNA exclusively in an 
exoribonuclelytic fashion (Schaeffer et al. 2009). Another example is that endoribonucleolytic 
cleavage is now known to be associated with nonsense-mediated decay. Nonsense-mediated 
decay is a vital cellular mechanism used to detect nonsense mutations and is used to prevent the 
expression of faulty proteins (Chang et al. 2007). This process was traditionally thought to occur 
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only in an exoribonucleolytic fashion (Gatfield et al. 2004); however, SMG6, a metazoan-
specific nonsense-mediated decay factor, is now recognized to be the catalytic endonuclease 
responsible for endoribonucleolytic cleavage of nonsense mRNA molecules (Eberle et al. 2009; 
Huntzinger et al. 2008). In addition, transcriptome-wide profiling of mammalian mRNA 
cleavage products demonstrated that there are a large number of endoribonucleolytic cleavage 
sites for mammalian mRNAs (Karginov et al. 2010; Bracken et al. 2011; Mercer et al. 2011). 
These cleavage sites are independent of Argonaute2, Drosha and miRNA-directed cleavage, 
suggesting that endoribonucleoytic cleavage is more wide spread in RNA metabolism than 
previously thought. 
1.2.2 Known Eukaryotic Endoribonucleases 
The scientific field studying ribonucleases have identified several eukaryotic 
endoribonucleases. The number of known endoribonucleases is much lower than that of 
exoribonucleases and may be a direct result of the prior lack of scientific attention given to these 
enzymes. The endoribonucleases are generally multi-functional proteins and possess a wide 
variety of functions in the cell. Some of the endoribonucleases do not have known molecular 
targets nor are their catalytic mechanisms known. The endoribonucleases that have been studied 
have varied target RNA substrates and catalytic mechanisms and possess many distinct functions 
in the eukaryotic cell (Li et al. 2010; Tomeki et al. 2010). 
Several identified endoribonucleases have weak evidence supporting their 
endoribonuclease activity. These endoribonucleases have no direct evidence for eukaryotic RNA 
cleavage, have no known cellular targets, or have no known catalytic site or mechanism. The 
eukaryotic protein ADP-ribosylation factor domain protein 1 (ARD-1) was found to duplicate 
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RNase E function in prokaryotes (Wang et al. 1994); however, there have not yet been any 
studies demonstrating endoribonuclease activity for this enzyme in eukaryotic cells. Aldolase C 
possesses a potential molecular target in the human low molecular weight neurofilament (NFL) 
mRNA molecule (Canete-Soler et al. 2005); but, the catalytic site for its endoribonuclease 
activity remains unknown (Stefanizzi et al. 2007). Polysomal ribonuclease 1 (PMR1) is a 
nuclease capable of cleaving mRNA endonucleolytically in the presence of a cofactor protein, 
heat shock protein 90 (Hsp90) (Peng et al. 2008). Although it is capable of RNA cleavage, 
PMR1 has no known cellular targets and does not have an identified catalytic site as the primary 
sequence of this protein does not match any known ribonuclease. Placental protein 11 (PP11) is a 
predicted endoribonuclease which shares its secondary structure with an amphibian 
endoribonuclease, XendoU (Laneve et al. 2008). In vitro experiments have shown that this 
protein is capable of endoribonuclease activity (Laneve et al. 2008), but no structural studies 
have shown eukaryotic RNase activity. 
Several of the identified endoribonucleases have distinct functions in eukaryotic cells 
owing to their endoribonuclease activity. Dicer and Argonaute 2 (AG02) play roles in the 
process of post-transcriptional gene-silencing. Dicer processes long double-stranded RNAs or 
short-hairpin RNAs in the cytoplasm into products which are involved in silencing target genes 
via the RNA-Induced Silencing Complex (RISC) complex (Kim et al. 2009). AG02 is 
recognized as the catalytic enzyme in the RISC complex, serving to degrade mRNA targeted by 
siRNAs and microRNAs (Liu et al. 2004). Given the role of Dicer and AG02 in gene silencing, 
these enzymes are implicated in a large variety of important physiological roles such as cellular 
development and maintenance (Knight et al 2001; Bernstein et al. 2003; Muljo et al. 2005). The 
previously mentioned Dis3/Rrp44 is the catalytic subunit of the exosome and is implicated in 
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regulating the cellular levels of many RNA species (Lorentzen et al. 2008). The PIN domain of 
Dis3/Rrp44 is thought to be responsible for the endoribonuclease activity (Schneider et al. 2009). 
The nonsense-mediated mRNA decay factor (SMG6) is responsible for catalytic activity for the 
process of nonsense-mediated decay (Eberle et al. 2009). Nonsense-mediated decay is a vital 
cellular process protecting cells from the expression of non-sense mutation containing mRNA 
molecules (Behm-Ansmant et al. 2007). The eukaryotic protein Angiogenin cleaves ribosomal 
RNA (rRNA) and transfer RNA (tRNA) (Saxena et al. 1992) and is implicated in protein 
synthesis. Inositol-requiring protein 1 (IRE1) regulates the expression of a protein involved in 
the unfolded protein response (UPR), X-box-binding protein 1 (XBP1) by splicing the mRNA 
transcript of XBP1 (Calfon et al. 2002). 
Of the identified endoribonucleases, only 2 have been identified to target specific mRNA 
in eukaryotic cells, which results in regulation of the expression of the targeted gene. 
Deregulation of these enzymes may lead to disease. For example, RNase L acts as a tumour 
suppressor through its endoribonuclease activity as mice deficient in RNase L have suppressed 
levels of apoptosis (Zhou et al. 1997; Malathi et al. 2004). Mutations of RNase L have also been 
linked with the development of prostate cancer (Silverman 2003). The second ribonuclease is 
apurinic/apyrimidinic endonuclease 1 (APE1). APE1 possesses endoribonucleolytic activity in 
vitro (Barnes et al. 2009) against c-myc Coding Region Determinant (CRD) RNA. Currently, the 
only known cellular target of APE1 is c-myc mRNA (Barnes et al. 2009) which was 
demonstrated using knock down experiments in a HeLa human cervical cancer cell line. As c-
myc is a powerful oncogene, it is possible that the deregulation of the ribonuclease activity of 
APE1, through amino acid substitution mutations, could play a role in the pathogenesis of 
cancer. 
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1.3 Apurinic/Apyrimidinic Endonuclease 1 (APE1) 
The APE I enzyme is a 36 kDa multifunctional protein and is found in the nucleus (Evans 
et al. 2000), cytoplasm (Tell et al. 2005) and mitochondria (Chattopadhyay et al. 2006). Its 
current known activities in the cell include: 1) endonuclease activity on abasic DNA (AP-DNA) 
in the Base Excision Repair (BER) pathway (Evans et al. 2000); 2) acting as a redox factor 
which activates transcription factors of many growth related genes (Evans et al. 2000); 3) 3'-5' 
exonuclease activity in removing deoxyribonucleoside analogues from DNA (Chou et al. 2000); 
4) endoribonucleolytic activity against mRNA in vitro (Barnes et al. 2009); and 5) endonuclease 
activity on abasic RNA (Berquist et al. 2008). All of these functions appear to play critical roles 
in eukaryotic organisms, whether through maintenance of genomic stability or the ability to 
directly regulate gene expression. The biochemical functions of the APE1 protein are localized to 
two distinct protein domains. Redox activity is localized to the N-terminal 61 amino acid 
residues (Evans et al. 2000) while the remaining nuclease-related activities are thought to occur 
in the remaining C-terminal amino acids (Chou et al. 2000; Berquist et al. 2008; Barnes et al. 
2009). 
1.3.1. Overview of Abasic DNA Cleavage Activity 
APE1 plays two major roles in BER pathway of DNA repair. First, it facilitates the 
proper orientation of the DNA substrate by removing the glycosylase protein from the DNA 
substrate (Baldwin et al. 2006). Second, it catalyzes the rate-limiting reaction of the BER process 
- the endonucleolytic cleavage of the phosphodiester backbone 5' to the abasic site (Srivastava et 
al. 1998). The C-terminal domain of APE1 has been implicated in this process - specifically, 
residues 61 through 318 (Fishel et al. 2007). Of these residues, several key amino acids have 
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been identified as playing vital roles in DNA cleavage and binding. The amino acids E96, D210 
and H309 are implicated in the actual cleavage mechanism of the abasic site (Gorman et al. 
1997; Mol et al. 2000; Beernink et al. 2001) while residue W280 is involved in substrate 
recognition. This residue achieves substrate recognition by using the aromatic structure of 
tryptophan and intercalating it with the abasic site of the AP-DNA (Kaneda et al. 2006). Residue 
C99 is implicated in binding of abasic DNA as mutations of this cysteine residue to a serine 
residue significantly reduced the ability of APE1 to bind AP-DNA in vitro (Mantha et al. 2008). 
Magnesium ions are required for AP-DNA cleavage activity and play a key role in the catalytic 
reaction by stabilizing reaction intermediates though binding to two metal co-ordination sites 
(Beernink et al. 2001). This magnesium ion is mobile and moves from one metal binding site to 
the other during the catalytic reaction as determined by molecular dynamics simulations 
(Oezgeun et al. 2007). Other residues which have been identified to play a role in abasic DNA 
cleavage include D60, D90, Y171, N212, D219, D283, D308 and residues (Tell et al. 2005) 
1.3.2 Possible Association of AP-DNAase Activity with Disease 
The role of APE1 and its AP-DNA cleavage in disease is difficult to ascertain. The DNA 
repair activity of APE1 has traditionally been considered a protective mechanism against 
diseases by removing deleterious mutations from genome (Fishel et al. 2007). However, there is 
compelling biochemical evidence that APE1 may play a direct role in not only the genesis of 
tumours but in disease progression and drug resistance. For example, significantly elevated 
levels of APE1 protein have been observed in several cancerous tissues such as osteocarcoma 
(Wang et al. 2004), cervical (Qing et al. 2009), lung (Wang et al. 2009), and ovarian cancers 
(Al-Attar et al. 2010). These elevated levels of APE1 protein are associated with both poor 
prognosis and drug resistance in patients with these cancers (Qing et al. 2009; Wang et al. 2004; 
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Wang et al. 2009; Al-Attar et al. 2010). Furthermore, the reduction of APE1 protein levels in 
vitro, using siRNA targeting methods, renders cancer cells sensitive to DNA damaging anti­
cancer therapies such as radiotherapy and chemotherapeutic agents including alkylating agents 
(Wang et al. 2004), anti-metabolites (McNeill et al. 2009), methanosulfates (Luo et al. 2004) and 
oxidizing agents such as H2O2 (Xiang et al. 2008). 
Currently, it is difficult to identify if the AP-DNA cleavage activity of APE1 is tumour 
suppressing or oncogenic. It may be the case that both scenarios are true and that APE1 may 
simply be one of many interacting genes which modulate the risk of various types of cancers. 
1.3.3 Overview of the Redox Activity of APE1 
In addition to its vital role in BER, APE1 appears to have another critical function in 
mammalian cells. This is the ability of APE1 to directly regulate gene expression through 
activation of various cellular transcription factors by reducing the transcription factors into their 
active states. Genes regulated by APE1 in this fashion, either directly or through a signalling 
cascade, regulate cell growth and division. This includes genes such as c-jun (Abate et al. 2007), 
c-fos (Xanthoudakis et al. 1992), Glial cell line-derived Neurotrophic Factor (GDNF) (Kim et al. 
2009), Multi Drug Resistance Gene 1 (MDRG1) (Chattopadhyay et al. 2008), nuclear factor 
kappa-light-chain-enhancer of activated B cells (nf-kB) (Ando et al. 2008), Phosphatase and 
Tensin Homolog (PTEN) (Fantini et al. 2008) and Vascular Endothelial Growth Factor (VEGF) 
(Wang et al. 2007). Using siRNA and proteomics, APE1 has been implicated in regulating a 
wide variety of cellular functions such as cell growth, apoptosis, intracellular redox state, 
mitochondrial function, and cytoskeletal structure (Vascotto et al. 2009). However, as the study 
showing these functions was carried out using APE1 knock down experiments, it is not entirely 
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clear if these modulated gene expression levels are due to the redox or endoribonuclease 
functionalities of APE1. 
The N-terminal domain of APE1, consisting of the 61 N-terminal amino acid residues, 
provides the redox function. Residues 1-61 are unique as they are not found in the primary 
sequence of other DNA repair enzymes. This N-terminal domain is thought to be able to function 
independently of the nuclease domain of APE1 for redox activities (Izumi et al. 2005). Of the 
first 61 amino acid residues, the residues E36 through T61 are vital for redox activity (Walker et 
al. 1993). It had been thought that the residue C65 played a major role in redox activity as 
demonstrated by C65 being required for mouse survivability (Walker et al. 1993). However, a 
2003 mutagenesis experiment has showed that this residue is not important for redox activity as 
mice with homozygous cysteine to alanine mutations at this position were able to survive to 
adulthood in good health (Ordway et al. 2003). As such, it appears that the C65 residue is no 
longer considered vital for redox activity of APE1. 
1.3.4 Possible Association of REDOX Activity with Disease 
As target genes for the redox activity of APE1 are so vital to cell function, it is likely that 
perturbation to the regulation of these genes may lead to the deregulation of cell phenotype and 
subsequently lead to disease pathogenesis. APE1, through its redox function, may act as a 
tumour suppressor gene by activating the expression of known tumour suppressor genes. An 
example of a known tumour suppressor gene which is regulated by the redox function of APE1 is 
p53 (Jayaraman et al. 1997). A loss of APE1 redox activity may lead to lowered levels of p53 
which in turn could lead to increased levels of oncogenic proteins. However, APE1 may also act 
as an oncogene by activating the expression of known proto-oncogenic genes or genes related to 
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cancer drug resistance and cancer progression such as c-jun (Xanthoudakis et al. 1992), c-fos 
(Xanthoudakis et al. 1992), NF-KP (Ando et al. 2008), VEGF (Wang et al. 2007), PTEN (Fantini 
et al. 2008) and estrogen receptors (Curtis et al. 2009). Elevated levels of these proteins in cells 
could result in cancer pathogenesis or cancerous cells becoming drug resistant. 
As in the case with AP-DNA cleavage activity, it is difficult to determine which role APE1 
plays in cancer through its redox function. Does it act like a tumour suppressor gene or an 
oncogene? There is evidence in the literature which point either way (Jayaraman et al. 1997; 
Xanthoudakis et al. 1992; Xanthoudakis et al. 1992; Ando et al. 2008; Wang et al. 2007; Fantini 
et al. 2008; Curtis et al. 2009). 
1.3.5 Overview of the Endoribonuclease Activity of APE1 
In 2009, researchers in Dr. Lee's lab purified and identified two endoribonucleases from 
rat liver polysomes that were capable of cleaving the oncogenic mRNA species, c-myc, in vitro. 
One of these proteins was subsequently identified to be APE1. APE1 was challenged with radio 
labelled c-myc CRD RNA in endoribonuclease assays and was found to preferentially cleave 
single stranded regions of RNA at UA, CA and UG dinucleotides (Barnes et al. 2009). 
Furthermore, this study identified that APE1 appears to regulate the cellular expression levels of 
c-myc in HeLa cervical cancer cell lines (Barnes et al. 2009). APE1 has not been identified to 
regulate the expression of any other gene in vitro. 
Some of the residues critical for this mRNA cleavage activity have been identified (Kim 
et al. 2011). These residues are very similar to the essential residues for AP-DNA cleavage 
activity (E96, H309) (Kim et al. 2011), implying a shared binding and catalytic site between the 
DNA and RNA cleaving activities. However, the actual mechanism of cleavage between DNA 
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and RNA is not likely to be the same due to the biochemical differences between DNA and 
RNA. In support of this, Dr. Lee's lab has further demonstrated that the cleavage mechanism of 
APE1 for RNA uses the 2' carbon hydroxyl group on the sugar ring in catalysis (Kim et al. 
2009). DNA has no hydroxyl group on the 2' carbon position, and thus, this mechanism of 
catalysis is impossible for DNA. Also, a 2009 study has demonstrated that an interaction 
between APE1 and another protein, Nucleophosminl (NPM1), enhances abasic DNA cleavage 
while inhibiting RNA cleavage (Vascotto et al. 2009). Together, these facts suggest a different 
catalytic site for each substrate type. 
The critical residues for binding RNA have not yet been fully elucidated; however, a 
2009 electrophoretic mobility shift assay (EMSA) study showed that the 33 N-terminal residues 
of the APE1 protein play a role in the binding of single stranded RNA. Removal of the 33 N-
terminal amino acids results in lost ability of the APE1 protein to bind single stranded RNA 
(Vascotto et al. 2009). These results suggest that this region is also important for the binding and 
catalytic function of APE1 for mRNA. 
1.3.6 Possible Association of Endoribonuclease Activity with Disease 
As mRNA regulation is now considered a key control point in the regulation of gene 
expression, and deregulation of these processes have been implicated in diseases, the possible 
role of the endoribonuclease function of APE1 in disease is compelling (Garneu et al. 2007). 
Deregulation of gene expression is a hallmark of many diseases, especially cancer. Thus, it is 
tempting to hypothesize that deregulation of gene expression, through loss of function mutations 
for the mRNAse activity of APE1, may lead to disease. This hypothesis is bolstered by the 
finding that APE1 appears to keep the cellular expression levels of a potent oncogene, c-myc, in 
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check in HeLa cervical cancer cell lines through its endoribonuclease activity (Barnes et al. 
2009). 
Some data however, indicate that the endoribonuclease activity of APEl is not 
responsible for cancer. If APEl is responsible for keeping oncogene expression levels in check, 
then the general over-expression (Qing et al. 2009; Wang et al. 2004) and cytoplasmic 
localization of wild type APEl in cancer tissues (Yoo et al. 2008; Kelley et al. 2001; Di Maso et 
al. 2007) appear to implicate that a mechanism other than endoribonuclease activity is 
responsible for disease. The complete picture of genes which are controlled by the 
endoribonuclease activity of APEl is not currently known and APEl may, in fact, be negatively 
regulating an unknown tumour suppressor gene via an endoribonucleoytic mechanism. 
1.4 Human Population Variants of APEl 
Studies have demonstrated that DNA repair genes are frequently subjected to single 
nucleotide polymorphisms and single amino acid substitutions such as in the case of X-ray 
Repair Cross-Complementing protein 1 (XRCC1) (Wang et al. 2009) and human 8-Oxoguanine 
DNA N-Glycosylase 1 (hOGGl) (Weiss et al. 2005). APEl is no different: 19 population 
variants of APEl have been identified and several of these variants have been examined for 
perturbations in the biochemical functions of APEl demonstrating associations with disease. 
1.4.1 Known Population Variants of APEl 
The following single amino acid substitution variants of APEl have been identified in the 
human population: K35Q, G39E, Q51H, G57A, I64V/T, L104R, PI 12L, E126D, D148E, 
R237A/C, G241R, D283G, G306A, P311S, T313A and A317V (Wilson etal. 2011). Of the 
listed mutations, K35Q, G39E, Q51H, G57A, I64V/T are located in the redox domain of the 61 
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N-terminal amino acids (Izumi et al. 2005). The remainders of the mutants (L104R, PI 12L, 
E126D, D148E, R237A/C, G241R, D283G, G306A, P31 IS, T313A and A317V) are located in 
the nuclease domain of APE1 at the C-terminal domain of the protein (Figure 1). The 
implications are that K35Q, G39E, Q51H, G57A, I64V/T are unlikely to have effects on 
nuclease function, including ribonuclease activity, whereas the remainder of the population 
variants may. Figure 1 illustrates the known population variants of APE1 and their locations 
relative to the functional domains of APE1. 
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Figure 1. The known human population variants of APE1 and their locations on the APE1 
protein relative to the known functional domains of APE1. (Wilson et al. 2011) 
Two known mutations in the 5' promoter region of the APE1 gene have been also 
identified. The first mutation is a T-»G SNP mutation at nucleotide position 141 (T-141G) 
which decreases the binding affinity of an APE1 transcription factor for this promoter region 
resulting in an overall decrease in the expression of APE1 protein levels (Lu et al. 2009). A 
16 
CHAPTER 1 - INTRODUCTION 
second mutation is known to occur at position -656 resulting in a SNP of T-»G (T-656G). In 
contrast to the (T-141G) variant, (T-656G) increases cellular levels of APEl and has thus been 
demonstrated to increase expression of APEl (Lo et al. 2009). 
1.4.2 Known Effects of the Population Variants on APEl Function 
The majority of the population variant studies on APEl have focused on the effects of the 
variants on the AP-DNA endonuclease activity. Two variants (Q51H and I64V) are excluded 
from these studies, as they are located in the redox domain of APEl and therefore will likely 
have no effect on nuclease functions of APEl (Izumi et al. 2005). The remainders of the variants 
have been assayed for their ability to cleave AP-DNA. The variants L104R, E126D and R237A 
possess a 40-60% reduction in overall AP-DNA cleavage activity as compared to wild-type 
APEl (Hadi et al. 2000). In contrast, G241R has a 10% increase in AP-DNA cleavage activity 
(Hadi et al. 2000). Both D148E and G306A have identical cleavage ability as compared to wild-
type APEl (Hadi et al. 2000). 
Experiments have been carried out to examine the effect of these variants on APEl 
endoribonuclease activity. When challenged with an 88-nt long c-myc RNA substrate, the 
D148E, R237A, G241R and G306A variants showed decreased RNA cleaving activity as 
compared to that of wild-type APEl (Kim et al. 2012). The L104R and E126D variants possess 
altered cleavage sites on the RNA substrate as both variants lost cleavage sites and gained 
additional unique cleavage sites, respectively, as compared to the cleavage sites of wild-type 
APEl (Kim et al. 2012). In addition to these altered cleavage patterns, these two variants 
maintained RNAse activity even in the presence of a powerful RNase inhibitor, RNasin (Kim et 
al. 2012). RNasin is a small peptide inhibitor of RNase activity which functions by the 
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noncovalent bonding of RNasin to RNases (Kim et al. 1999). Wild-type APEl no longer 
possesses RNase activity in the presence of RNasin. The ability of L104R and E126D to cleave 
in the presence of RNasin suggests that these variants may be more active in their RNase activity 
than APEl. A summary of the effects of the population variants on the nuclease functions of 
APEl are listed below in Table 1. Population variants not characterized for nuclease activity are 
not listed. 
Table 1. APEl human population variants and their effects on nuclease activity for AP-DNA and 
c-myc CRD RNA. Reductions in cleavage activity are relative to wild-type APEl. 
Mutant Effect on AP-DNA Endonuclease 
Activity 
Effect on RNA Cleaving Activity 
D148E 
No effect (same as wild-type APEl) Lost cleavage activity (Kim et al. 
(Hadi et al. 2000) 2009) 
Altered cleavage sites on c-myc CRD 
E126D 
40-60% reduction in cleavage 
activity (Hadi et al. 2000) 
RNA substrate (Loss of wild-type 
APEl clevage sites, addition of novel 
cleavage sites) (Kim et al. 2009) 
Altered cleavage pattern (Loss of 
L104R 
40-60% reduction in cleavage wild-type APEl clevage sites, 
activity (Hadi et al. 2000) addition of novel cleavage sites) 
(Kim etal. 2009) 
R237A 
40-60% reduction in cleavage Lost cleavage activity (Kim et al. 
activity (Hadi et al. 2000) 2009) 
G241R 
Slightly enhanced cleavage activity Lost cleavage activity (Kim et al. 
(Hadi et al. 2000) 2009) 
G306A 
No effect (same as wild-type APEl) Lost cleavage activity (Kim et al. 
(Hadi et al. 2000) 2009) 
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1.4.3 Known Associations of the Population Variants of APE1 to Diseases 
Several population variants of APE1 have been documented in the literature for 
association with human diseases. In contrast, some variants appear to confer a protective effect to 
diseases. Select variants display a correlation with disease as well as a correlation with a 
protective effect. Despite the large number of studies on the APE1 variants and disease, there are 
few studies attempting to link these associations with any biochemical function of APE1. The 
association of the APE1 population variants with disease remains an intriguing issue with no 
clear mechanism. 
There are two documented mutations of APE1 which occur in the 5' promoter region of 
the gene. In population studies where APE1 was sequenced, the T-141G variant appears to 
confer protective effects against cancer pathogenesis in lung cancer when compared to 
individuals carrying the wild-type version of APE1 (Lu et al. 2009; Li et al. 2011; Zhou et al. 
2011). In contrast, the T-656G variant increases the risk of lung cancer in similar studies (Lo et 
al. 2009). 
The I64V variant was originally identified in a DNA sequencing experiment from lung 
cancer and healthy tissues from a Norwegian population. Healthy individuals had a statistically 
higher occurrence of I64V, compared to wild-type APE1, thus implicating a protective effect of 
this population variant against lung cancer (Zeinolddiny et al. 2006). However, when the I64V 
variant is present in conjunction with an environmental risk factor (vinyl chloride monomer), 
there is a higher risk of lung cancer as compared wild-type APE1 (Wen-Bin et al. 2009). 
The L104R and E126D variants were first identified in a screening study for APE1 in 
relation to Amyotrophic Lateral Sclerosis (ALS). Sequencing of individuals resulted in the 
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identification of these variants in individuals displaying the disease (Olkowski et al. 1998). 
These findings suggest that the L104R and E126D variants may have a role in the pathogenesis 
of ALS; however, subsequent studies have shown the absence of both these variants from larger 
screening experiments, indicating these variants may not be implicated in ALS (Hayward et al. 
1999; Tomkins et al. 2000). No known studies have implicated these variants in cancer. 
The majority of studies of APE1 population variants have focused on the D148E variant. 
This may be due to its high allele frequency in the human population as it is present in roughly 
0.380% of the general population with an allele distribution of D/D = 54, D/E = 45 and E/E = 25 
(Hadi et al. 2000). The D148E variant has been shown to be associated with a wide variety of 
cancers such as bladder (Narter et al. 2008), colon (Pardini et al. 2008; Kasahara et al. 2008; 
Canbay et al. 2011), lung (Ito et al. 2004; Agachan et al. 2009; Gangwar et al. 2009), pancreatic 
(Jiao et al. 2006), prostate (Chen et al. 2008), and stomach cancers (Canbay et al. 2011) in 
various DNA sequencing experiments. The D148E variant is capable of causing an increased risk 
of cancer for both homo and heterozygous substitutions (Narter et al. 2008; Pardini et al. 2008; 
Agachan et al. 2009). In addition, the majority of the studies show that the APE1 variant, by 
itself, is capable of causing an increased risk of cancer (Narter et al. 2008; Gangwar et al. 2009; 
Canbay et al. 2011). However, some studies demonstrate that the APE1 polymorphism requires 
associations with polymorphisms of other DNA repair proteins, such as XRCC1 or hOGGl, to 
facilitate an increase in cancer risk (Jiao et al. 2006; Chen et al. 2008). Despite the quantity of 
studies which demonstrate an association of D148E with increased cancer risk, there are almost 
an equal number of studies demonstrating either no increase in risk or an outright protective 
effect against various forms of cancer. These studies include cancers such as bladder (Terry et al. 
2006; Gangwar et al. 2009), esophageal (Tse et al. 2009), head and neck (Li et al. 2007), lung 
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(Misra et al. 2003; Zeinolddiny et al. 2006; Chang et al. 2009), pancreatic (Li et al. 2007), 
stomach (Li et al. 2009; Palli et al. 2010) and thyroid cancers (Chiang et al. 2008) for this 
D148E variant. 
Known associations of APEl variants and their effects on several human diseases are 
contradictory. There is still current research being performed in regards to identifying the 
relationship of these variants with cancer. However, the D148E variant has been most recently 
shown to be associated with cancer instead of being shown to be protective against cancer 
(Canbay et al. 2011). Thus, investigation into the biochemical functions of how the APEl 
variants may be causing disease is of interest. Table 2 summarizes the APEl population variants 
risk and diseases. 
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Table 2. Human APEl population mutants and their associations with disease. Risk can be 
mediated by only the presence of an APEl polymorphism (denoted as 'alone') or by the 
combination of APEl and other DNA repair protein polymorphisms (denoted as 'mixed'). | 
indicates an increased risk of disease, while j indicates a decreased risk of disease. 
Type of Disease Variant 
D14SE 164V T-I4IG T-656G 
Bladder Cancer 
|Risk(Narter et al. 
2008) 
(alone) 
Risk (Gangwar et 
al. 2009) 
(alone) 
No Change (Terry 
et al. 2006) 
| Risk (Wang et 
al. 2010) 
(alone) 
Colon Cancer 
t Risk (Paradini et 
al. 2008) 
(mixed) 
t Risk (Canbay et 
al. 2011) 
(alone) 
| Risk (Kasahara 
et al. 2008) 
(alone) 
| Risk (Kasahara 
et al. 2008) 
(mixed) 
Esophageal Cancer No Change (Tse et 
al. 2009) 
Head and Neck No Change (Li et 
al. 2007) 
Lung Cancer 
t Risk (Ito et al. 
2004) 
(mixed) 
No Change 
(Chang et al. 
2009) 
| Risk 
(Zeinolddiny et al. 
2006) 
(alone) 
J, Risk (Lu et al. 
2009) 
(alone) 
f Risk (Lo et al. 
2009) 
(mixed) 
| Risk (Shen et al. 
2005) 
(alone) 
| Risk (Agachan 
etal. 2009) 
(alone) 
t Risk (Gangwar 
et al. 2009) 
(mixed) 
No Change 
(Zeinolddiny et al. 
2006) 
No Change (Misra 
etal. 2003) 
| Risk (Wen-Bin 
etal. 2009) 
(mixed -
Environmental 
Toxin - vinyl 
chloride 
monomer) 
[ Risk (Li et al. 
2011) 
(alone) 
| Risk (Zhou et al 
2011) 
(alone) 
Pancreatic Cancer 
t Risk (Jiao et al. 
2006) 
(mixed) 
4 Risk (Li et al. 
2007) 
(alone) 
Prostate Cancer 
t Risk (Tse et al. 
2008) 
(mixed) 
Skin Cancer 
| Risk (Breton et 
al. 2007) 
(alone) 
Stomach Cancer 
No Change (Li et 
al. 2009) 
(alone) 
t Risk (Canbay et 
al. 2010) 
(alone) 
No Change (Palli 
etal. 2010) 
(alone) 
Thyroid Cancer 
No Change 
(Chiang et al. 
2008) 
(alone) 
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1.5 Research Objectives 
There are numerous pieces of evidence implicating the population variants of APE1 in 
human diseases. In particular, the D148E variant has been implicated in many types of cancers 
(Narter et al. 2008; Pardini et al. 2008; Kasahara et al. 2008; Canbay et al. 2011; Jiao et al. 
2006; Tse et al. 2008; Canbay et al. 2011) while the L104R and E126D variants have been 
shown to be associated with ALS (Olkowski et al. 1998). It is hypothesized that these variants 
cause a change in the biochemical activity of APE1 which leads to downstream cellular changes 
and thus disease. However, the exact biochemical function of APE1 that is being affected which 
ultimately leads to disease by these variants remain unknown at this time. Previous work has 
identified the variants to have full or modestly reduced AP-DNA cleavage activity as compared 
to the wild-type APE1, suggesting that the DNA endonuclease activity of APE1 is not likely 
responsible for disease (Hadi et al. 2000). In conjunction with the AP-DNA activity, the RNA 
cleaving activity of D148E is lost while the L104R and E126D variants have altered RNA 
cleavage patterns as compared to wild-type APE1 (Kim et al. 2012). Given that the AP-DNA 
activity of D148E, L104R and E126D variants was not significantly altered (Hadi et al. 2000), 
we hypothesize that the link between these variants and human disease may be explained by their 
significantly altered ribonuclease activity (Kim et al. 2012). This forms the basis for the research 
objectives of this thesis. 
The first objective of this thesis was to demonstrate if the population variants of APE1, 
when expressed in a prokaryotic system, would cause an altered phenotype (in this case, growth) 
for the cells when compared to wild-type APE1 expression. The system used was the Origami™ 
(DE3) cells. Due to mutations for cellular reductases, these Origami™ (DE3) cells allow for 
proper folding of proteins and formations of structurally important cysteine bonds. For instance, 
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proper folding of ribonucleases in Origami™ (DE3) cells results in cellular death (Smith et al. 
TTV/f 2006). Wild-type APEl and the population variants were expressed in Origmai cells and the 
subsequent levels of cytotoxicity were observed. The results were expected to answer two 
questions: 1) Are the previously observed in vitro RNA cleaving activity relevant in a cellular 
system?; 2) Is there a correlation between ribonucleolytic activity and cell cytotoxicity in 
Origami™ (DE3) cells exerted by APEl and its human population variants? 
The second objective arises from the results of the first objective. Here, the primary 
objective was to demonstrate if the population variants, when expressed in mammalian cells, 
would cause an altered phenotype upon expression as compared to the wild-type APEl 
expression. Two cell lines were chosen for the thesis experiments, HeLa cervical cancer cells and 
HepG2 liver cancer cells. APEl and its population variants were expressed in these cells and the 
subsequent effect on growth rate were measured using a standard MTT growth assay. The results 
were expected to give insight into whether the population variants of APEl are relevant in 
mammalian systems for causing phenotypic changes and thus possibly leading to downstream 
disease. 
The third objective of this thesis was to investigate if the population variants of APEl 
caused alterations in the mRNA levels of specific genes leading to growth rate changes in 
mammalian cells as measured by MTT assays. APEl and its population variants were expressed 
in mammalian cells at which point total RNA was harvested and subjected to microarray 
analysis. Given the preliminary microarray data, real time quantitative polymerase chain reaction 
analysis was then used to examine alterations of mRNA levels of selected genes upon over-
expression of APEl and its population variants. The results were expected to demonstrate if 
APEl causes phenotypic changes in mammalian cells owing to its endoribonuclease activity. 
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Chapter 2 
A Prokaryotic System in Assessing the Ribonuclease activity of 
Human Population Variants of APE1 
2.1 Introduction 
This chapter is dedicated to the experimental approaches used to investigate the cellular 
cytotoxicity contributed by the ribonucleolytic activity of APE1 and its population variants in a 
prokaryotic system, Origami™ (DE3) cells. In addition, this section will cover data presentation 
and analysis as well as implications in mammalian systems. 
In 2009, APE1 was identified as an endoribonuclease capable of cleaving c-myc CRD 
RNA in vitro and regulating c-myc mRNA levels in HeLa cells (Barnes et al. 2009). The finding 
could place APE1 as having a role in the pathogenesis of diseases as mRNA turnover is 
identified as a key control point in gene expression for eukaryotes (Garneau et al. 2007). In 
addition, several population variants of APE1 exist (Wilson et al. 2011), and some of these 
variants demonstrate altered RNA cleavage in vitro (Kim et al. 2012). It is possible that these in 
vitro findings could translate to the variants possessing altered ribonuclease function in cellular 
systems, and possibly to pathogenesis in organisms. Indeed, mutations to an endoribonuclease 
known as RNase L have been shown to play a role in the development of prostate cancer 
(Silverman 2003). However, before investigation of the APE1 variants in a mammalian system 
could be performed, it was deemed appropriate to determine if these variants have any cellular 
effect in a simple and more easily manageable biological system. 
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The system chosen for analysis in prokaryotic cells was the Origami™ (DE3) cells. 
These cells are a strain of E. coli with specific mutations to their thioredoxin reductase and 
glutathione reductase genes (Smith et al. 2006). These mutations result in an oxidizing 
cytoplasm conducive for disulfide bond formation for any exogenously introduced protein via 
plasmid transformation (Smith et al. 2006). In the case of ribonucleases, proper folding of the 
yw 
exogenous protein will result in measureable cytotoxicity of the Origami (DE3) cells, 
ostensibly due to RNA cleavage. Origami™ (DE3) cells have been used to demonstrate the RNA 
cleaving function of the endoribonucleases RNase A (Smith et al. 2006) and Angiogenin (Smith 
et al. 2008). 
Two separate assays were performed: 1) a transformation efficiency based plate protocol; 
and 2) a transformation efficiency independent liquid broth protocol. The population variants 
analyzed in detail were the Q51H, I64V, L104R, E126D, D148E and G306A APE1 variants. 
2.2 Methodology 
2.2.1 Preparation of pET15b-APEl Constructs 
A plasmid construct consisting of the vector pET15b and the APE1 cDNA containing a 
Q51H mutation was donated to our lab by Dr. Sankar Mitra from the University of Texas 
Medical Branch at Galveston. From this, our lab generated the pET15b-APEl wild-type plasmid 
construct as well as the pET15b-I64V and pET15b-D148E population variants via site directed 
mutagenesis (Kim et al. 2009). The pET15b-APEl construct was subsequently used to generate 
the remaining population variant constructs (L104R, E126D, and G306A) using a PCR-based 
site directed mutagenesis protocol. Table 3 lists the primers used for the site-directed 
mutagenesis. A 50 (j.1 reaction mixture was prepared containing 100 ng of pET15b-APEl 
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(template), 3.6 mM dNTPs, 1.1 pM forward primer, 1.1 (J.M reverse primer, IX Phusion DNA 
polymerase buffer and 0.04 units of Phusion DNA polymerase (Finnzymes Scientific). The PCR 
reaction was carried out in an MJ Research MiniCycler using the following PCR cycle: 
Denaturation at 95°C for 45 seconds, primer annealing at 55°C for 45 seconds and extension at 
68°C for 10 minutes for a total of 18 cycles. This was followed by a final 20 minute extension 
step at 68°C and storage at 4°C. DNA sequencing by Macrogen Inc. (Seoul, South Korea) was 
used to confirm the identity of the population variant pET-15b vectors. 
Table 3. List and sequence identity of primers used for generation of population variant pET-15b 
plasmid constructs. Highlighted nucleotides are responsible for the amino acid substitution. 
Plasmid Construct Forward Primer Reverse Primer 
L104R 5'-TCA GAG AAC AAA CGA CCA GCT GAA CTT-3' 
5'-AAG TTC AGC TGG TCG 
TTT GTT CTC TGA-3' 
E126D 5'-cct TCG GAC AAG GAC GGG TAC AGT GGC-3' 
5'-GCC ACT GTA CCC GTC 
CTT GTC CGA AGG-3' 
G306A 5' -TCC AAG GCC CTC GCC AGT GAT CAC TGT-3' 
5'-AC A GTG ATC ACT GGC 
GAG GGC CTT GGA-3 
2.2.2 Preparation of Competent Origami™ (DE3) Cells 
Origami™ (DE3) cells were acquired from Novagen (Germany). Origami™ (DE3) cells 
contain resistance genes towards the kanamycin and puromycin antibiotics. For selection 
purposes, all plates and liquid cultures used for culturing Origami™ (DE3) cells contained 12.5 
Hg/ml of kanamycin and 100 ng/ml of puromycin. Cells were streak plated and grown overnight 
at 37°C. Single colonies were selected and cultured overnight in 10 mL cultures at 37°C by 
shaking at 200RPM in an Innova40™ shaker. Five ml of these overnight cultures were then 
subcultured into 500 ml cultures and grown at 37°C and 200 RPM until the optical cell density 
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(OD600) was determined to approach 0.400 absorbance units using a DU 800 UV/visible 
spectrophotometer. Cells were spun down in an Allegra X-12R Centrifuge for 30 minutes at 
3500 RPM and re-suspended in 30 ml cold CaCl2 for 30 minutes. Cells were re-centrifiiged at 
3500 RPM for 120 minutes and re-suspended in 4 ml of CaCI2 solution containing 15% glycerol. 
Cells were split into 100 |xl aliquots and kept at -80°C until use. 
2.2.3 Preparation of LB-Ampicillin Plates 
Agar containing Luria Broth (LB) was melted using a microwave. Upon liquefaction, 
ampicillin was added to the LB-agar to a final concentration of 100 ng/ml. 15 ml of the LB-Amp 
was then aliquoted into 100 mm Petri dishes (Fisherbrand, UK) and allowed to solidify at room 
temperature. Plates were then stored at 4°C until used. 
2.2.4 Plate Protocol for Assessment of Cytotoxicity of APE1 and its Population 
Variants in Origami™ (DE3) Cells 
pGEX4T3-RNase A vector construct was generously gifted for use in this experiment by 
Dr. Ronald Raines, University of Wisconsin-Madison. 100 ng of pGEX4T3-RNase A, empty 
vector pET15b, pET15B-APEl or pET15B containing the population variants of APE1 
(pET15B-Q51H, pET15B-I64V, pET15B-L104R, pET15B-E126D, pET15B-D148E, pET15B-
G306A) were pipetted to single aliquots of Origami™ (DE3) cells and incubated on ice for 30 
minutes. The cells were then transformed via heat shock at 42°C for 60 to 75 seconds and 
expanded with 1 ml of LB broth. After thorough mixing, 150 ^1 was then then plated onto 
ampicillin plates (100 jxg/ml) partitioned into thirds for comparison of transformation conditions. 
Plates were left to incubate overnight at 37°C and the resulting colonies for each transformation 
condition were counted. Images were acquired using the Alpha Innotech Chemilmager and 
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FluroChem 5500 software. Data from 3-5 biological replicates were performed for each 
transformation. Statistical analysis were performed by normalizing the number of surviving 
colonies of each of the population variant transformed cells to that of wild-type APE1-
transformed cells and then performing a one way analysis of variance (ANOVA) test. 
In addition to the 100 ng transformation previously carried out, transformations using 300 
ng and 500 ng of empty pET15b, pET15b-APEl, pET15b-L104R, and pET15b-E126D plasmid 
constructs were performed. Statistical analyses were performed using a one way ANOVA test as 
previously described. 
2.2.5 Broth Protocol for Assessment of Cytotoxicity of APE1 and its Population 
Variants in Origami™ (DE3) Cells 
Individual Origami™ (DE3) colonies containing empty pET15-b vector or pET15b-
APE1 constructs (pET15b-APEl, pET15b-Q51H, pET15b-I64V, pET15b-L104R, pET15b-
E126D, pET15b-D148E, pET15b-G306A) were prepared. Single 100 ml aliquots of cells were 
transformed with 100 ng of plasmid and subsequently heat shocked at 42°C for 1 minute. Upon 
transformation, cells were plated on LB-Ampicillin (100 |Ag/ml) plates and grown overnight. 
Individual colonies of each plasmid transformed cell type were then selected and picked using a 
sterile loop and transferred to 1 ml of LB-Ampicillin broth (100 (xg/ml). The cultures were then 
grown for one hour at 37°C. The cell counts for each of the plasmid transformed cell types were 
then determined using a previously established standard curve for E. coli cell density at OD6oo-
Cell Count = 1.09(OD6oo)3 3,58 
All plasmid transformed cell types were then equalized to a common cell count using LB-
Ampicillin broth and subsequently transferred to 96-well tissue culture plates in triplicates. The 
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initial OD^o was measured for each plasmid transformed cell type and recorded as the initial cell 
count at time point zero. The culture plates were then placed in an Innova40™ incubator shaker 
set at 37°C and 200 rpm to facilitate cell growth. The tissue culture plates were removed from 
the incubator and the OD600 taken for each sample type every hour after the initial reading for a 
total of 12-15 hours. The data obtained were plotted as growth curves in Kaleidagraph 4.0™ 
(Synergy Software, USA). Subsequently, the generation time for each transformation was also 
determined using KaleidaGraph 4.0™ (Synergy Software, USA) using the equation fit parameter 
((0.693147/ml)*m0)*m2;ml=5;m2=0.05 
V 
which describes doubling time of bacterial cells during the exponential growth phase where the 
m variables describe the shape, starting and end points of the fitted curve. The data collected 
from 3-5 biological replicates were then pooled and standard deviation was calculated. 
2.3 Results 
To determine if the plate assay was suitable for detecting differences in cellular 
cytotoxicity, and by extension ribonucleolytic activity, a control plate was performed using 
pET15b-Empty vector as a negative control and pGEX4T34T3-RNase A as a positive control. 
Previously, transfonnation of pGEX4T34T3-RNase A had been demonstrated to be completely 
cytotoxic to cells and resulted in no surviving colonies (Raines et al. 2006). A plasmid dosage of 
300 ng was chosen as the initial plasmid concentration since previous studies in our lab had 
demonstrated that this amount of plasmid was suitable for the study of APE1 in Origami™ 
(DE3) cells. Here, the empty vector pET15b-transformed Origami™ (DE3) cells produced many 
colonies (Figure 2A, section 1), consistent with no introduced exogenous protein. In contrast, the 
pGEX4T3-RNase A-transformed cells resulted in total cell death and no resultant surviving 
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colonies due to the expression of RNase A (Figure 2A, section 3). As an intermediary condition, 
the pET15b-APEl -transformed cells produced fewer colonies than the empty-vector-
transformed-cells but more colonies than the pGEX4T3-RNase A-transformed cells (Figure 2A, 
section 2). Thus, there was a discernible sensitivity in detecting increases in cytotoxicity between 
condition types; here we see cytotoxicity of wild-type APE1 but to a lesser degree than that of 
RNase A. Therefore, this assay was deemed suitable for determining possible differences in 
cytotoxicity between wild-type APE1 and its population variants. 
Origami ™ (DE3) cells transformed with the plasmid pET15b-Q51H showed an equal 
number of surviving colonies compared to wild-type APE1 transformation (Figure 2B, section 1 
versus section 2). This was again observed for the I64V (Figure 2B, section 3 versus section 2), 
D148E (Figure 2D section 1 versus section 3), and G306A variants (Figure 2D section 1 versus 
section 3). At least 3 biological replicates were performed for each plasmid type. ANOVA 
analysis confirmed that the Q51H, I64V, D148E and G306A-transformed cells did not produce a 
statistically significant decrease in surviving colonies as compared to wild-type APE1-
transformed cells (Figure 4). In contrast, both the L104R and E126D variants resulted in 25% 
and 35% surviving colonies as compared to the wild-type APE1, respectively (Figure 2C, section 
1 versus section 2 and Figure 2C, section 3 versus section 2, respectively). At least 3-5 
biological replicates were performed for these variants, and ANOVA analyses confirmed that the 
L104R and E126D transformations were more cytotoxic to Origami™ (DE3) cells than the 
wild-type APE1 transformations (P < 0.0001) (Figure 4). 
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Figure 2. Growth of Origami (DE3) cells on LB-Ampicillin plates after transformation with 
various pET15b plasmid constructs. Plates were incubated at 37°C for 24 hours. 300 ng plasmid 
of: 
A: 1) empty vector petl5b; 2) pET15B-APEl; 3) RNase A pGEX4T3 
B: 1) pET15b-Q51H; 2) pET15B-APEl; 3) pET15b-I64V 
C: 1) pET15b-L104R; 2) pET15B-APEl; 3) pET15b-E126D 
D: 1) pET15b-D148E; 2) pET15B-APEl; 3) pET15b-G306A 
To further investigate the mechanism for this observed increase in cytotoxicity, an 
experiment was devised to test for various concentrations of plasmid transformation (100 ng, 300 
ng and 500 ng) (Figure 3). Each transformation condition was performed in biological triplicates. 
For 100 ng plasmid transformation, L104R and E126D-transformed cells showed 25% and 35% 
surviving colonies compared to that of the wild-type APE1, respectively (Figure 3 A, section 1 
versus section 2 and Figure 3 A section 3 versus section 2 respectively). One way ANOVA shows 
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that this difference is significant (P < 0.0001) (Figure 4). This trend held true for the 300 ng 
transformation (Figure 3B, section 1 versus section 2 and Figure 3B section 3 versus section 2, 
respectively) where the L104R transformation resulted in 25% surviving colonies and the E126D 
transformation resulted in 30% surviving colonies as compared to the wild-type APEl 
transformations (Figure 4). One way ANOVA shows that this difference is significant (P < 
0.0001) (Figure 4). However, for the 500 ng transformations, the L104R transformation no 
longer showed any significant difference in surviving colonies as compared to the wild-type 
APEl transformation (Figure 3C, section 1 versus section 2) while the E126D transformation 
still showed a decreased number of colonies as compared to wild-type APEl (Figure 3C, section 
3 versus section 2). 
Figure 3. Growth of Origami™ (DE3) cells on LB-Ampicillin plates after transformation with 
varying dosages of the L104R, E126D and Wild-type APEl pET15B plasmid constructs. Plates 
were incubated at 37°C for 24 hours. 
A: 100 ng plasmid of 1) pET15b-L104R; 2) pET15B-APEl; 3) pET15b-E126D 
B: 300 ng plasmid of 1) pET15b-L104R; 2) pET15B-APEl; 3) pET15b-E126D 
C: 500 ng plasmid of 1) pET15b-L104R; 2) pET15B-APEl; 3) pET15b-E126D 
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120 
Figure 4. Percent surviving colonies of Origami™ (DE3) cells post transformation with the 
indicated pET15b plasmid construct and dosage normalized to Wild-type APEl survival. L104R 
and E126D at both 100 ng and 300 ng have P < 0.0001 using a one way ANOVA test as 
indicated by *. (n = 3-5) 
To further confirm the results obtained using the plate protocol, a second assay was 
developed using Origami™ (DE3) cells. In contrast to the plate assay, the second broth assay 
measures doubling time of Origami™ (DE3) cells in liquid culture, where a longer doubling time 
indicates increased cytotoxicity and a lower doubling time indicates decreased cytotoxicity. 
Additionally, as an advantage, this method no longer counts surviving colonies and thus 
eliminates the dependency on transformation efficiency. Initially, wild-type APEl and empty 
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vector were transformed. From this, it was determined that wild-type APEl resulted in a longer 
doubling time (1.78 +/- 0.17 hours) than the empty vector (1.22 +/- 0.16), indicating cell 
cytotoxicity due to ribonuclease activity of APEl (Figure 5 and Table 4). Thus, further 
experiments with the population variants were carried out. From pooling and analyzing 3 
biological replicates, the assay determined that the L104R and E126D APEl population variants 
had significantly longer doubling times (2.84 +/- 0.15 and 2.48 +/- 0.19 hours, respectively) as 
compared to that of the wild-type APEl or the empty vector (Figure 5 and Table 4). The 
remainder of the population variants did not show any significant changes in doubling time 
(Table 4). 
vector 
WT 
— L104R 
HEL- E126D 
» 0.2 
4 6 8 
Time (hours) 
12 
Figure 5. Example growth curve and fitted trend line for determining the doubling time of 
Origami™ (DE3) cells when transformed with various pET15b plasmid constructs, (n = 1) 
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Table 4. List of transformation conditions and the resulting doubling times for Origami™ (DE3) 
cells in the broth protocol, n = 4 for empty vector, APE1, L104R and E126D. n = 3 for Q51H, 
I64V, D148E and G306A. Data obtained using KaleidaGraph 4.0 
Transformation Condition Doubling Time (Hours) 
pETl 5b-Empty Vector 1.22 ± 0.16 
pET15b-APEl 1.78 ±0.17 
pET15b-Q51H 1.52 ±0.10 
pET15b-I64V 1.58 ±0.08 
pET15b-L104R 2.84 ±0.15 
pET15b-E126D 2.48 ±0.19 
pET15b-D148E 1.63 ±0.11 
pET15b-G306A 1.82 ±0.08 
2.4 Discussion 
Origami™ (DE3) cells have been used in many instances for generating properly folded 
and functional proteins which can then be used for many downstream applications. Some of 
these include NMR studies (Ponniah et al. 2010), immunological studies (Wang et al. 2010), and 
functional studies for screening ribonucleolytic activities of proteins (Raines et al. 2006; Raines 
et al. 2008). As such, the proteins expressed in this study are properly folded wild-type APE1 
and APE1 population variants. It may not be clear which function or functions of APE1 
(ribonuclease, AP-DNA nuclease, redox regulation of transcription factors) are responsible for 
any observed effects in this experiment. However, given that two of the major other functions of 
APE1 (AP-DNA nuclease and redox regulation of transcription factors) are based on eukaryotic 
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specific cellular functions (eukaryotic gene expression regulation and eukaryotic genomic 
stability regulation) it is unlikely that these functions are responsible for the cytotoxicity 
observed here in a prokaryotic system. Hence, the observed cytotoxicity is likely attributable to 
the endoribonuclease activity of APE1. 
The results of this study clearly demonstrated the ability of these assays to determine an 
increase in cellular cytotoxicity. This was observed for wild-type APE1 transformed cells 
compared to no exogenous protein-expressed cells (empty vector) (Figure 2A, section 2 versus 
section 1). Similarly, the L104R and E126D-transformed cells demonstrated increased 
cytotoxicity as compared to wild-type APE 1-transformed cells (Figure 4 and Table 4). These 
results agree with previous experiments where RNase A demonstrated cytotoxicity (Raines et al. 
2006). Furthermore, subsequent experiments using both the plate and broth protocols in our lab 
have demonstrated cellular cytotoxicity for a potential ribonuclease, 60S ribonuclease protein L9 
(RPL9) (unpublished data). 
The Q51H, I64V, D148E, and G306A APE1 variants were found to have no increased 
cytotoxicity in either assay (Figure 4, Table 4). As such, these variants possess endoribonuclease 
activity which is comparable to wild-type APE1. However, the D148E and G306A variants were 
shown to have decreased ribonucleolytic activity compared to wild-type APE1 in previous in 
vitro endoribonuclease assays (Kim et al. 2012). The in vitro ribonuclease activity of the D148E 
and G306A APE1 variants should have translated to an increase in surviving colonies in the plate 
method or a decrease in doubling time in the broth method. However, neither scenario was 
observed (Figure 2, D148E and G306A versus wild-type APE1 and Table 4, D148E and G306A 
versus wild-type APE1). It is possible that both these assays are simply not sensitive enough to 
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detect differences in decreased endoribonuclease activity between APE1 population variant 
types. 
In contrast, the L104R and E126D APE1 variants were shown to be significantly more 
cytotoxic than wild-type APE1 to the Origami™ (DE3) cells (Figure 4, Table 4), suggesting that 
these variants have enhanced endoribonuclease activity as compared to wild-type APE1. In the 
plate protocol, this was observable for transformations at two plasmid concentrations, 100 ng and 
300 ng (Figure 4). However, the trend was no longer true at 500 ng (Figure 3C, section 1 versus 
section 2). This result may be explained by the following: qualitatively, there is an increasing 
number of surviving colonies as the concentration of plasmid for transformation is increased 
(Figure 3A versus Figure 3B versus Figure 3C). Such an observation has been observed 
previously, where an increase in the concentration of pGEX4T3-Angiogenin resulted in an 
increase in the number of surviving colonies (Raines et al. 2006). This may indicate greater 
transformation efficiency as plasmid concentration is increased and may serve as an explanation 
for the observed 500 ng plasmid transformation reported here: transformation efficiency may 
simply be outpacing cytotoxicity at this concentration resulting in a surplus of colonies for all 
transformation conditions and subsequent masking of cytotoxicity variation. The remaining 
cytotoxicity of E126D at this concentration (Figure 3C, section 3) may imply a stronger 
cytotoxicity for this variant as compared to L104R. For the broth assays, the doubling time of 
L104R and E126D were significantly higher than that of the wild-type APE1 (Section 2.2). Since 
this is the first study to use Origami™ (DE3) broth assay to assess ribonuclease activity, there 
are no previous benchmarks to compare the results obtained here. However, unpublished results 
in our lab for a potential ribonuclease, 60S ribonuclease protein L9 (RPL9), also showed 
increased doubling times. This, as well as the results from the plate assay, demonstrates an 
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increase in ribonuclease activity for the L104R and E126D variants as compared to the wild-type 
APE1. 
The observed cytotoxicity of the L104R and E126D variants correlates with altered in 
vitro endoribonuclease activity for these variants. The L104R and E126D variants generated 
cleavage sites on a c-myc CRD RNA substrate that are unique (Kim et al. 2012). These variants 
are also especially active in vitro, with RNA cleaving activity observed even in the presence of 
the powerful RNase inhibitor, RNasin (Kim et al. 2012). The results from the plate experiments 
may provide some insight into the relative ribonucleolytic activity of these variants in cells. Both 
variants exhibited a 30% to 40% reduction in surviving colonies as compared to the wild-type 
APE1 (Figure 4). Previous experiments, as well as data obtained in this thesis, have shown that a 
ribonuclease with strong activity, such as RNase A, will result in complete cellular death with no 
surviving colonies (Smith et al. 2006). The weaker cytotoxicity effect of APE1 demonstrates that 
APE1 has weak ribonuclease activity when compared to RNase A. However, the increased 
cytotoxicity by the variants shows that they have increased or altered ribonucleolytic activity as 
compared to the wild-type APE1. The level of cytoxicity of the variants displayed here do not 
match that of RNase A, suggesting that these variants do not possess strong ribonucleolytic 
activity as compared to that of RNase A. In summary, the L104R and E126D variants have 
stronger ribonucleolytic activity than that of the wild-type APE1 while possessing weaker 
activity than that of the potent and well-studied RNase A. 
The mechanism for the observed increase in cytotoxicity for L104R and E126D may be 
explained by the molecular changes that these mutations cause to the APE1 protein. A study 
using molecular modeling has previously demonstrated that both the L104R and E126D variants 
may be of importance to the global conformation of the APE1 protein. Amino acid 104 of APE1 
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is positioned in a loop between P-sheet number 2 and a-helix number 3 (Hadi et al. 2000). This 
area is directly adjacent to the nucleic acid binding and recognition site. It was hypothesized that, 
upon substitution of the lysine residue with an arginine residue, the hydrophobic interactions 
between LI04 and its neighboring residues (L72, LI08, and W119) is disrupted resulting in a 
change in the structure of APE1 (Hadi et al. 2000). This would result in a novel positively 
charged region of the protein which may translate into an increased attraction of the negatively 
charged RNA substrate into the binding and catalysis pocket. This could explain the altered in 
vitro RNA cleaving activity previously observed (Kim et al. 2012) as well as the possible 
increase in RNA cleaving activity observed in this experiment for this variant (Figure 4, Table 
4). E126D presents an interesting case as the amino acid substitution here results in simply a 
reduction of one methylene group and no modifications to the overall or local charge of the 
protein. However, location of this residue is also positioned in a vital location relative to the 
secondary structure of APE1. El26 is located between P-sheet number 3 and 4 and is in close 
proximity to the DNA phosphate backbone (Hadi et al. 2000). This shortening of the amino acid 
side-chain may result in a change to the mobility of the p-sheets resulting in an increased 
opportunity for RNA binding and cleavage. Future investigations using crystal structures of these 
variants bound to RNA substrates could elucidate the exact binding and cleaving mechanisms 
which lead to this observed cytotoxicity. 
To summarize, the population variants L104R and E126D had increased cytotoxicity to 
TW 
Origami (DE3) cells in both assays used, suggesting an increase in ribonuclease activity. The 
remaining population variants, including D148E, demonstrated no discernible difference in 
cytotoxicity as compared to wild-type APE1, suggesting no change in ribonuclease activity. 
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How biologically relevant are these increases in cytotoxicity for the L104R and E126D 
variants? Previously, it has been demonstrated that the angiogenesis function of angiogenin is 
caused by the ribonucleolytic activity of the protein (Kelemen et al 1999). This function is vital 
for angiogenesis in tumor formation. In addition, the ribonucleolytic function of angiogenin was 
clearly demonstrated by death of these Origami™ (DE3) cells (Smith et al. 2008). As such, any 
observed changes to the survivability of Origami™ (DE3) cells due to the population variants of 
APE1 are likely to translate into a biologically relevant eukaryotic system. 
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Chapter 3 
Eukaryotic Systems in Assessing the Effects of Over-expressing 
APEl Population Variants 
3.1 Introduction 
This chapter describes the investigations into the possible phenotypic changes in 
eukaryotic cells upon over-expression of the two APEl population variants, L104R and E126D. 
Preliminary investigations into the possible molecular mechanisms for the observed phenotypic 
changes were undertaken using microarray analysis and quantitative real time polymerase chain 
reaction (qRT-PCR). 
In Chapter 2, both the L104R and E126D variants were shown to possess enhanced 
cytotoxicity in a prokaryotic system. This correlated with previous in vitro work which 
demonstrated unique RNA-cleaving activity of these variants (Kim et al. 2012). Various APEl 
population variants have previously been identified to be associated with cancers (Narter et al. 
2008; Pardini et al. 2008; Kasahara et al. 2008; Jiao et al. 2006; Tse et al. 2008; Canbay et al. 
2011). Therefore, it is warranted to investigate the effect these variants may have upon over-
expression in eukaryotic cells. In this thesis, two cancer cell lines were used: human cervical 
cancer cells (HeLa cells) and human hepatoma cancer cells (HepG2). Initial experiments were 
performed to determine if endogenous APEl plays a role in the growth of HeLa and HepG2 
cells. To achieve this, small interfering RNA (siRNA) technology was used to knock down 
endogenous APEl expression. Growth analyses, as measured by an increase in the number of 
cells, were carried out using 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide 
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(MTT) Assays. Concurrent research in Dr. Lee's lab had suggested that localization of APE1 to 
P-bodies, a focal point of mRNA turnover, was facilitated by stress. To induce such stress, 
sodium arsenite was used in the HepG2 growth analyses to facilitate localization of APE1 and its 
population variants to the P-bodies. 
Gene expression analysis studies were conducted in an effort to link altered gene 
expression, through the endoribonuclease activity of the APE1 variants, with the displayed 
altered phenotype when the variants were over-expressed in HepG2 cells. Two methodologies 
were used: 1) Microarray analysis, to quickly screen a large number of potential mRNA targets 
of the population variants; and 2) qRT-PCR, to confirm the results obtained from the microarray 
analyses. 
3.2 Methodology 
3.2.1 Preparation of pCMV5.1-APEl-FLAG Constructs 
The pCMV5.1-FLAG vector was purchased from OriGene Technologies Inc. (Rockville, 
MD) containing the APE1 cDNA sequence. This construct was subsequently used to generate 
pCMV5.1-L104R-FLAG and pCMV5.1-E126D-FLAG constructs via site-directed mutagenesis 
as previously described in section 2.1.1. Table 5 lists the primers used for the site-directed 
mutagenesis. Sequence identity was confirmed by DNA sequencing performed by Macrogen Inc. 
(Seoul, South Korea). 
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Table 5. Sequence identity of primers used for generation of population variant pCMV5.1-FLAG 
plasmid constructs. Highlighted nucleotides are responsible for the amino acid substitution. 
Plasmid Construct Forward Primer Reverse Primer 
5'-TCA GAG AAC AAA CGA CCA 5'-AAG TTC AGC TGG TCG 
GCT GAA CTT-3', TTT GTT CTC TGA-3' 
5'-CCT TCG GAC AAG GAC GGG 5'-GCC ACT GTA CCC GTC 
TAC AGT GGC-3' CTT GTC CGA AGG-3' 
3.2.2 Growth Rates of HeLa cells with APE1 Knockdown 
Human cervical cancer cells (HeLa) were purchased from the American Type Culture 
Collection (ATCC) and were subsequently cultured in T25 flasks containing Minimum Essential 
Medium (MEM) supplemented with 10% fetal bovine serum at 37°C in 5% CO2. The HeLa cells 
were then trypsinized for 5 minutes and the cells expanded using 10 ml of fresh medium. Cell 
counts were then determined using a Bright-Line Haemocytometer (Hausser Scientific) and the 
cell density adjusted to appropriate levels for plating cells at a concentration of 5xl04 cells per 
well using MEM. Cells were subsequently plated into 6 well tissue culture plates, in 
experimental duplicates, at 5xl04 cells per well in a total of 2 ml of volume. The next day, cells 
were transfected with either siRNA targeting APE1 or a scramble negative construct via 
Lipofectamine 2000 (Invitrogen, United States) using the following protocol: mixing of 2.5 )jtl of 
siRNA (final concentration of 20 nM) or scramble negative DNA (final concentration 20 nM) 
with 250 fil Opti-MEM and incubation for 15 minutes; mixing of 2.5 fxl of Lipofectamine 2000 
with 250 (il Opti-MEM and incubation for 15 minutes; mixing of these two Opti-MEM fractions 
and incubation for 30 minutes; replacement of media with 1.5 ml of fresh MEM medium; finally, 
addition of 500 |il of combined siRNA or scramble negative and Lipofectamine to the wells of 
the 6 well plates containing cells. The transfected cells were incubated overnight at 37°C in 5% 
44 
L104R 
E126D 
CHAPTER 3 - EUKARYOTIC SYSTEMS 
CO2. The sequences of the double stranded RNA sequences used in this experiment are in Table 
6. 
Table 6. Sequence identity of double stranded RNA used for transfection into HeLa and HepG2 
cells. The majority of the constructs are comprised of ribonucleotides (r). The sense constructs 
contain two deoxyribonucleotides (d). 
dsRNA Sense Antisense 
Construct 
APE 1 -sRNAi r(GUCUGGUACGACUGGAGUACCGG)dCA r(UGCCGGUACUCCAGUCGUACC AG ACCU) 
Scramble 
Negative- r(CUUCCUCUCUUUCUCUCCCUUGU)dGA r(UCACAAGGGAGAGAAAGAGAGGAAGGA) 
dsRNAi 
Cells were trypsinized and counted, then expanded with fresh medium and re-plated, in 
triplicates, into 96-well tissue culture plates in concentrations of 500,1000,1500 or 2000 cells 
per well in a total volume of 200 p.1 each. The cells were incubated overnight at 37°C in 5% CO2. 
Cells were then subjected to MTT assay analysis for the subsequent 5 days in 24 hour 
intervals - 24,48, 72,96 and 120 hours after plating. A solution containing the MTT dye 
Thiazolyl Blue Tetrazolium Bromide (Sigma-Aldrich, United States) was diluted to 175th 
concentration using fresh MEM medium. Subsequently, 50 nl of this solution was added to the 
wells of the 96 well plates and left to incubate at 37°C and 5% CO2 for 3 hours. Following 
incubation, 220 |il of medium was aspirated from each well and replaced with 150 jal of DMSO 
to dissolve and suspend the dye. Absorbance at 570 nm was then measured on a 
spectrophotometer as a measure of cell growth. Growth curves were prepared using 
Kaleidagraph 4.0™ (Synergy Software, USA). A total of 3 biological replicates were performed. 
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3.2.3 Growth Rates of HeLa Cells Over-expressing APE1 Population Variants 
HeLa cells were prepared for transfection in 6-well tissue culture plates as previously 
described in section 3.2.2. The transfection mixture for these experiments consisted of 1 |a.g of 
each of pCMV5.1-FLAG, pCMV5.1-Wild-typeAPEl-FLAG, pCMV5.1-L104R-FLAG, or 
pCMV5.1-E126D-FLAG plasmid constructs. Subsequent transfection, incubation and MTT 
analysis were performed as previously described in section 3.1.2. Growth curves were produced 
using Kaleidagraph 4.0™ (Synergy Software, USA) and a total of 3 biological replicates were 
performed. 
3.2.4 Preparation of pCMV6-XL5-APEl Constructs 
pCMV6-XL5-APEl constructs were prepared by subcloning the APE1 or population 
variant (L104R and E126D) cDNA sequences from the pCMV5.1-Wild-typeAPEl -FLAG 
plasmid constructs used in the previous HeLa experiments. The wild-type APE1, L104R and 
E126D cDNA sequences were amplified via PCR to remove the FLAG tag and 3' UTR using the 
following primers: forward: 5'-CGA GGT CTG GTC CGT CTG GAG TAC-3 and reverse: 5'-
GTA CTC CAG ACG GAC CAG ACC TCG-3. Amplification of the cDNA was carried out in a 
MJ Research MiniCycler with the following PCR cycle: Denaturation at 95°C for 45 seconds, 
primer annealing at 55°C for 45 seconds and extension at 68°C for 10 minutes for a total of 18 
cycles. pCMV6-XL5 was then purchased from OriGene Technologies Inc. (Rockville, MD). 
Approximately 1 jig of each type APE1 cDNA, generated from the PCR reactions (Wild-
type, L104R and E126D), and 1 |ig of pCMV6-XL5 empty vector were then subjected to an 
overnight double restriction digest using EcoRI (Invitrogen, United States) and Xbal (New 
England BioLabs, Massachusetts). The digestion was carried out at 37°C using 10 units each of 
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enzyme in a total reaction volume of 100 pi. Ligation reactions were then carried out using an 
insert to vector molar ratio of 3:1. The restriction digested APE1 cDNA inserts, restriction 
digested pCMV6-XL5 vector and 1 unit of T4 DNA Ligase (New England Biolabs, 
Massachusetts) were incubated for 2 hours at room temperature to generate ligated pCMV6-
XL5-APE1 constructs. Identification of the clones were carried out by restriction digest and 
comparison of subsequent insert band sizes compared to previously established APE1 cDNA 
sequence size (obtained from the pCMV5.1-FLAG constructs) on a 1% agarose gel. Identities of 
the plasmid constructs were confirmed by DNA sequencing at Macrogen Inc. (Seoul, Sorth 
Korea). 
3.2.5 Confirmation of Knockdown of APE1 in HepG2 Cells 
Human hepatoma cancer cells (HepG2) were purchased from ATCC and subsequently 
maintained and passaged in T25 flasks containing MEM medium supplemented with 10% fetal 
bovine serum at 37°C at 5% CO2. Cells were counted and plated into 6-well tissue culture plates, 
in experimental duplicates, at 5xl04 cells per well in a total of 2 ml of volume. The next day, 
cells were transfected with either siRNA targeting APE1 or scramble negative constructs via 
Lipofectamine 2000 (Invitrogen, United States) as previously described in section 3.2.2. Table 6 
describes the double stranded RNA sequences used for this experiment. The transfected cells 
were incubated overnight at 37°C in 5% CO2. 
At 48 and 72 hours post transfection, total cellular lysates were collected from the siRNA 
and scramble negative construct transfected wells. From the cellular lysates, 200 pi of 8M Urea 
was added to each well and the cells scraped from the wells using a plate scraper. The lysates 
were then subjected to 3 cycles of freezing at -80°C, thawing at 42°C and vigorous vortexing. 
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Samples were centrifuged at 13000 RPM in an Eppendorf Centrifuge 5415 R for 10 minutes at 
4°C. The supernatants containing the cellular proteins were collected and stored at -20°C until 
further use. Protein concentration was determined using a standard Bradford assay (Bio-Rad, 
California). 
From the total cellular lysates, 80 |xg of protein for each sample type were loaded onto a 
10% sodium dodecyl sulfate (SDS) polyacrylamide gel and electrophoresed for 1 hour at 100V. 
Upon completion of electrophoresis, proteins were transferred from the SDS polyacrylamide gel 
onto Amersham™ Hybond™-ECL paper (GE Healthcare, United Kingdom) via a Bio-Rad 
transfer device at 100V for one hour. The ECL paper was then subjected to Western analysis via 
incubation with 1/3000 dilution human APE1 and human P-Actin monoclonal antibodies 
(Affinity Bioreagents, Colorado) for 2 hours at room temperature and 1/3000 horseradish 
peroxidase conjugated secondary mouse monoclonal antibodies (Promega, Wisconsin) for one 
hour at room temperature. Chemiluminescence of samples were achieved using Pierce 
SuperSignal© West Pico Chemiluminescent Substrate kit and the resulting images were captured 
using an Alpha Innotech Chemilmager cabinet and FluroChem 5500 software. 
3.2.6 Growth Rates of HepG2 Cells with APE1 Knockdown 
HepG2 cells were prepared and transfected with siRNA and scramble negative sequences 
(Table 4) as previously described in secion 3.1.5. Cells were then counted and plated to 96 well 
plates in experimental triplicates. Finally, water or sodium arsenite (final concentrations of 0 
mM, 0.5 mM or 1.0 mM of sodium arsenite) (Sigma-Aldrich, United States) were added to the 
wells containing the cells. 
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MTT analysis for 0, 24,48, 72,96,120 and 144 hours post-transfection were carried out 
as previously described in section 3.1.2. The resulting data was used to generate growth curves in 
Kaieidagraph 4.0™ (Synergy Software, USA). A total of 3 biological replicates were performed. 
3.2.7 Confirmation of Over-expression of APE1 and its Variants in HepG2 Cells 
HepG2 cells were prepared as described in section 3.1.5 and transfected with 1 ug each of 
the pCM V 6-XL5-V ector, pCMV6-XL5-Wild-typeAPEl, or pCMV6-XL5-L104R plasmid 
constructs. At 72 hours post transfection, total cellular protein were collected from the pCMV6-
XL5-Vector, pCMV6-XL5-Wild-typeAPEl, or pCMV6-XL5-L104R transfected wells using the 
standard Urea lysis protocol as described previously in section 3.1.5. 
Total cellular protein was loaded directly onto Amersham™ Hybond™-ECL paper. 
Protein loaded per dot ranged from 25 ug to 1.56 ug in 2 fold dilution steps. In addition, 0.1 jig 
of recombinant human APE1 was loaded as a control. The ECL paper containing the protein 
samples were incubated with human APE1 monoclonal antibody (Affinity Bioreagents, 
Colorado) (1/3000 dilution) or human (3-actin monoclonal antibody (Sigma-Aldrich, United 
States) (1/3000 dilution) for 2 hours at room temperature. The ECL paper was then incubated 
1/3000 dilution horseradish peroxidase conjugated secondary monoclonal mouse antibodies 
(Promega, Wisconsin) for 1 hour at room temperature. Chemiluminescence of samples were 
achieved using Pierce SuperSignal© West Pico Chemiluminescent Substrate kit and the resulting 
images were captured using an Alpha Innotech Chemilmager cabinet and FluroChem 5500 
software. 
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3.2.8 Growth Rates of HepG2 Cells Over-expressing APE1 Population Variants 
HepG2 cells were prepared as described in section 3.1.5 and transfected with 1 |xg each of 
the pCMV 6-XL5-V ector, pCMV6-XL5-Wild-typeAPEl, pCMV6-XL5-L104R, or pCMV6-
XL5-E126D plasmid constructs. Cells were counted and plated to 96 well plates in experimental 
triplicates. Finally, water or sodium arsenite (final concentrations of 0 mM, 0.5 mM or 1.0 mM 
sodium arsenite) (Sigma-Aldrich, United states) were added to the wells containing the cells. 
MTT analysis for 0,24, 48, 72,96,120 and 144 hours post transfection were carried out 
as previously described in section 3.2.2 and the resulting data were used to generate growth 
curves in Kaleidagraph 4.0™ (Synergy Software, USA). A total of 3 biological replicates were 
performed. Subsequent two way ANOVA statistical analyses were performed using GraphPad 
Prism 5.0 (GraphPad Software, California). 
3.2.9 Isolation of mRNA for Microarray and qRT-PCR Analysis of Gene Expression 
HepG2 cells were prepared and transfected as previously described in section 3.2.2 with 
1 ng each of the pCMV6-XL5-Vector, pCMV6-XL5-Wild-typeAPEl, or pCMV6-XL5-L104R 
vectors. Forty-eight hours after transfection, mRNA was harvested from each transfection type 
using the mi'rVana™ mRNA isolation kit (Ambion, Texas). To each transfection type, 200 JJ.1 of 
Lysis/Binding buffer were added and the cells mechanically scraped from the wells using a pipet 
tip. Homogenate Additive was added to a 1/10th volume of the lysis mixtures and the mixtures 
were kept on ice for 10 minutes. An equal volume of acid phenol chloroform (pH = 4.5) was then 
added to the mixtures and the mixtures were centrifuged at 5 minutes at 10,000RPM. The upper 
phase containing nucleic acids were carefully aspirated and transferred to the supplied filter 
cartridges. The cartridges containing mRNA were then washed once with 700 fj.1 of Wash Buffer 
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1 and twice with 500 |il of Wash Buffer 2. mRNA was eluted from the collection cartridges 
using 90°C nuclease free water. mRNA was stored at -80°C until further use. RNA samples were 
then subjected to DNA cleanup via using 1000 units of DNase I (Promega, Wisconsin) incubated 
at 1 hour at 37°C. mRNA samples were then measured using a Nanodrop spectrophotometer to 
determine the A260/A280 OD ratio and aliquoted into 20 |il aliquots for storage at -80°C until 
further use. 
3.2.10 Microarray Analysis and Preliminary qRT-PCR 
mRNA harvested from a single biological replicate of pCMV6-XL5- Vector, pCMV6-
XL5-Wild-typeAPEl, and pCMV6-XL5-L104R transfected HepG2 cells were sent to the 
Hospital for Sick Children in Toronto for microarray analysis. Two genes of interest were chosen 
for subsequent qRT-PCR analysis - BCL2A1 and RASEF. Primers used for the qRT-PCR 
experiments were chosen based on previous gene expression studies analyzing these genes -
BCL2A1 from a study concerning anti-apoptosis in human neutrophils (Lee et al. 2006) and 
RASEF from a paper identifying RASEF as a tumour suppressor gene in uveal melanoma (Maat 
et al. 2008). c-MYC and P-Actin primers were chosen from gene study experiments previously 
undertaken in Dr. Lee's lab (Barnes et al. 2009). Table 7 lists the gene identities and subsequent 
primers used for the qRT-PCR analysis. In addition to the mRNA harvested for the microarray 
analysis, one additional biological replicate of mRNA was used for the qPCR experiments. 
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Table 7. List of primers and sequence identity of primers used for qRT-PCR analysis 
Gene 
Identity Forward Primer Reverse Primer 
BCL2A1 
RASEF 
c-MYC 
P-Actin 
5'-CCA GGC AGA AGA TGA GAG­
S' 
5'-TTC CTC TTC CAA CTC ACT 
CAA CTG-3' 
5'-ACG AAA CTT TGC CCA TAG 
CA-3' 
5'-TTG CCG ACA GGA TGC AGA 
AGG A-3' 
5'-CTG GCA GTG TCT ACG GAC-3' 
5'-ATC AGA CTT CAA AGC ACA GAA 
ATG-3' 
5'-GCA AGG AGA GCC TTT CAG AG­
S' 
5'-AGG TGG ACA GCC AGG CCA 
GGA T-3' 
First strand cDNA was synthesized for all subsequent qRT-PCR applications using 
iScript cDNA™ Synthesis Kit (Bio-Rad). From the total RNA, 1 jj.g of RNA from each 
transfection type was mixed with 4 pi of 5X reaction mix, 1 p.1 of reverse transcriptase and 
nuclease-free water to a final volume of 20 (xl. First strand cDNA synthesis was carried out in a 
MJ Research MiniCycler with the following PCR cycle: 25°C for 5 minutes, 42°C for 30 
minutes, 85°C for 5 minutes and storage at 4°C until removal from the MiniCycler unit. cDNA 
was synthesized fresh for each experiment and was used immediately in downstream 
applications upon synthesis. All subsequent qRT-PCR applications were carried out using an IQ5 
qRT-PCR cycler (Bio-Rad, California). The dye used for detection of amplification was iQ™ 
SYBR® Green Supermix (Bio-Rad, California). 
Melt curve analyses were carried out on two primers sets (BCL2A1 and RASEF). cDNA 
was pooled from three transfection conditions (pCMV6-XL5-Vector, pCMV6-XL5-Wild-
typeAPEl and pCMV-XL5-L104R) and the analyses conducted at a range of temperatures from 
52°C to 62°C. Melt curves were generated using the iQ5 software (Bio-Rad, California). Gene 
expression studies were carried out using the following cycle conditions: 3 minutes at 95°C for 
one cycle followed by 40 cycles of 10 seconds at 95°C and 30 seconds at 60°C. Gene expression 
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values were calculated by the iQ5 software (Bio-Rad, California) using the ddCT method with 0-
Actin acting as the reference gene as per previously established in the Lee lab (Barnes et al. 
2009). 
3.3 Results 
3.3.1 Growth Rates of HeLa cells with APE1 Knockdown 
The first step towards analyzing the effects of APE1 population variants on mammalian 
cells was to determine if APE1 plays a role in the modulation of growth rate in HeLa cells. To 
determine this, experiments were performed to knock down endogenous levels of APE1 protein 
and observe the effects upon growth rate. Four cell densities, based on previous MTT 
experiments carried out in Dr. Lee's lab using mammalian cells (Bassett 2007), were chosen for 
this experiment - 500,1000,1500 and 2000 cells per well. Qualitative observations from a single 
biological replicate were analyzed for each cell density. Over a five day period, there was no 
observable difference in growth rates between knockdown APE1 HeLa cells versus control HeLa 
cells at the cell densities of 500 cells per well (Figure 6A), 1000 cells per well (Figure 6B), 1500 
cells per well (Figure 6C) or 2000 cells per well (Figure 6D) over the 5 day period. Two 
additional biological replicates were performed, with similar qualitative growth patterns 
observed (data not shown). 
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Figure 6. Representative growth rate of HeLa cells over a five day period when transfected with 
either siRNA targeting APE1 (APE1 Knockdown HeLa cells) or scramble negative RNA 
(Control HeLa cells). A single biological replicate is shown for each cell plating density (n = 1). 
All biological replicates growth displayed this growth pattern. 
A: 500 cells per well; B: 1000 cells per well; C: 1500 cells per well; D: 2000 cells per well 
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3.3.2 Growth Rates of HeLa Cells Over-expressing APE1 Population Variants 
The next experiment was to over-express the L104R and E126D APE1 variants in HeLa 
cells to observe potential changes in growth rate as compared to the wild-type APE1. The same 
four cell densities used in section 3.2.1 were chosen for these experiments - 500,1000,1500 and 
2000 cells per well. Qualitative observations from a single biological replicate were analyzed for 
each cell density. There were no observable differences between growth rates between L104R 
APE1 HeLa cells or E126D APE1 HeLa cells versus wild-type APE1 HeLa cells at the cell 
densities of 500 cells per well (Figure 7A), 1000 cells per well (Figure 7B), 1500 cells per well 
(Figure 7C) or 2000 cells per well (Figure 7D) over the 5 day period. In addition, there was no 
difference in growth rate when comparing wild-type APE1 HeLa cells to that of empty-vector 
HeLa cells for all cell densities (Figure 7A, 7B, 7C and 7D) at all points during the growth assay. 
Two additional biological replicates were performed, with similar qualitative growth patterns 
observed (data not shown). 
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Figure 7. Representative growth rate of HeLa cells over a five day period when transfected with 
pCMV5-Vector (Empty Vector), pCMV5.1-Wild-typeAPEl-FLAG (Wild-type APE1), 
pCMV5.1 -LI04R-FLAG (L104R APE1) or pCMV5.1-E126D-FLAG (E126D APE1). A single 
biological replicate is shown for each cell plating density (n = 1). All biological replicates 
displayed this growth pattern. 
A: 500 cells per well; B: 1000 cells per well; C: 1500 cells per well; D: 2000 cells per well 
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3.3.3 Growth Rates of HepG2 Cells with APE1 Knockdown 
To assess if APE1 plays a role in the modulation of growth rate in HepG2 cells, APE1 
was knocked down and growth rates were observed. A single cell density was chosen for these 
experiments (2000 cells per well) as the previous HeLa cell experiments demonstrated that cells 
nearly reached confluency over a 5 day period at this concentration. As HepG2 cells are known 
to grow slower than HeLa cells, the experiment was expanded to cover six days instead of five 
days. Concurrent research in Dr. Lee's lab had shown that APE1 localized to the cytoplasm of 
HepG2 cells upon treatment with 0.1 to 1.0 mM sodium arsenite (Kim S-E, unpublished 
observation). Thus, three concentrations of sodium arsenite were chosen for this experiment - 0 
mM, 0.5 mM and 1.0 mM. Qualitative analysis from a single biological replicate was performed. 
At 0 mM sodium arsenite, there was no observable change in growth rate between APE1 
knockdown HepG2 cells versus control HepG2 cells for the first 24 and 48 hours (Figure 8A). 
However, starting at 72 hours and continuing on through 144 hours, there was an observable 
decrease in cell growth rate for APE1 knockdown HepG2 cells as compared to the control 
HepG2 cells (Figure 8A). At 0.5 mM sodium arsenite, there was no change in growth rate for the 
first 24 hours; however, there was a noticeable decrease in growth rate for APE1 knockdown 
HepG2 cells starting at 48 hours continuing through 144 hours (Figure 8B). A similar growth 
pattern was observed for 1.0 mM sodium arsenite - at 24 hours there was no discernible 
difference in growth rate with a noticeable decrease in growth rate for APE1 knockdown HepG2 
cells starting at 48 hours (Figure 8C). The general effect of the sodium arsenite stressor was 
cytotoxicity to the HepG2 cells (Figure 8, compare A to B to C) while retaining the overall 
growth pattern. The highest growth of the HepG2 cells was reduced from a final absorbance (570 
nm) value of approximately 2.00 for no sodium arsenite (Figure 8A) to 0.55 for 0.5 mM sodium 
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arsenite (Figure 8B) to 0.50 for 1.0 mM sodium arsenite (Figure 8C). Two additional biological 
replicates were conducted and showed the similar qualitative results (data not shown). 
To confirm that the change in growth rate observed was due to knockdown of APEl 
protein levels, Western blot analysis was performed on proteins isolated from APEl knockdown 
HepG2 cells and control HepG2 cells. For 48 hours post transfection, there was a decrease in 
APEl protein expression for the APEl knockdown HepG2 cells as compared to the control 
HepG2 cells (Figure 9, compare lanes 1 to 2). APEl protein levels were also reduced at 72 hours 
post transfection in APEl knockdown HepG2 cells versus control HepG2 cells (Figure 9, 
compare lanes 3 to 4). p-Actin levels remain constant throughout both transfection conditions 
and time (Figure 9, compare lanes 1 through 4) indicating that the knock down of APEl was 
specific. This also indicated equal loading of protein samples in each well. The timing of the 
knock down of APEl correlates with growth curve data - the 0 mM sodium arsenite growth 
curves show a decrease in cell growth for APEl knockdown HepG2 cells starting at 72 hours 
post transfection (Figure 8A) while the 0.5 mM and 1.0 mM sodium arsenite show decrease of 
growth starting at 48 hours post transfection (Figure 8B, 8C). These results of suggest that 
endogenous APEl plays a role in facilitating the growth of HepG2 cells. 
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Figure 8. Representative growth rates generated from incubating HepG2 cells transfected with 
either siRNA targeting APEl (APEl Knockdown HepG2 cells) or scramble negative RNA 
(control HepG2 cells) over a six day period at indicated concentrations of sodium arsenite. A 
single biological replicate is shown for each concentration of sodium arsenite (n = 1). All 
biological replicates displayed this growth pattern. 
A: 0 mM sodium arsenite; B:0.5 mM sodium arsenite; C: 1.0 mM sodium arsenite 
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Figure 9.Western blot analysis of protein isolated from HepG2 cells transfected with siRNA 
targeting APEl (APEl Knockdown HepG2 Cells) or scramble negative RNA (Control HepG2 
cells). 80 }xg total cellular protein was loaded for wells 1-4; 0.1 (ig recombinant human APEl 
was loaded to lane 5 as a positive control. Samples were subjected to incubation with human 
APEl and human p-actin monoclonal antibodies (n = 1). 
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3.3.4 Growth Rates of HepG2 Cells Over-expressing APEl Population Variants 
We next examined the effect of over-expressing L104R and E126D APEl variants on the 
growth of HepG2 cells in the presence or absence of sodium arsenite (0 mM, 0.5 mM and 1.0 
mM sodium arnsenite). Qualitative observations were taken from a single biological replicate. At 
0 mM sodium arsenite, there was an observable increase in cellular growth rate of wild-type 
APEl HepG2 cells as compared to that of empty vector HepG2 cells starting at 72 hours and 
continuing on throughout the 144 hour test period (Figure 10A). There was also a modest, 
qualitative increase in cellular growth rates with L104R APEl HepG2 cells and E126D APEl 
HepG2 cells when compared to both wild-type APEl HepG2 cells and empty vector HepG2 cells 
at all time periods starting at 24 hours (Figure 10A). A qualitative trend was observed for cells 
incubated with 0.5 mM sodium arsenite: wild-type APEl HepG2 cells exhibited enhanced cell 
growth rate as compared to empty vector HepG2 cells starting at 72 hours while the L104R 
APEl HepG2 cells and E126D APEl HepG2 cells exhibited enhanced growth rate compared to 
both wild-type APEl HepG2 cells and empty vector HepG2 cells starting at 72 hours (Figure 
10B). However, this trend did not continue with 1.0 mM sodium arsenite incubation; there may 
have been minor enhanced cellular growth for E126D APEl HepG2 cells at 48 hours and L104R 
and E126D HepG2 cells at 96 hours (Figure 10C). This difference is qualitatively reduced 
compared to that observed in both the 0 mM and 0.5 mM sodium arsenite treated cells. There is 
no qualitative difference in growth rate between transfection conditions for the remainder of the 
times analyzed in the 1.0 mM transfection (Figure 10C). Two additional biological replicates 
were conducted and similar qualitative results were obtained (data not shown). 
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Figure 10. Representative growth curves generated from incubating HepG2 cells transfected with 
pCMV6-XL5- Vector (Empty Vector), pCMV6-XL5-Wild-typeAPEl (Wild-type APEl), 
pCMV6-XL5-Ll 04R (L104R APEl) or pCMV6-XL5-E126D (E126D APEl) plasmid constructs 
over a six day period incubated at indicated concentrations of sodium arsenite. A single 
biological replicates is shown for each concentration of sodium arsenite (n = 1). All biological 
replicates displayed this growth pattern. 
A: 0 mM sodium arsenite; B: 0.5 mM sodium arsenite; C: 1.0 mM sodium arsenite. 
Statistical analysis of three biological replicates of the 0 mM sodium arsenite experiments 
was undertaken using two way ANOVA. A post-test analysis comparing the growth rate of wild-
type APEl HepG2 cells to the L104R and E126D APEl HepG2 cells at each time point was 
performed. There were no statistical differences in the growth rates of wild-type APEl HepG2 
cells as compared to the growth rates of the L104R and E126D APEl HepG2 cells at 0 hours, 24 
hours and 48 hours (Figure 11). However, at 120 hours (P < 0.05) and 144 hours (P < 0.05), 
L104R APEl HepG2 cells grew significantly faster compared to wild-type APEl HepG2 cells 
(Figure 11). E126D APEl HepG2 cell growth rates were observed to be significantly faster as 
compared to wild-type APEl HepG2 cells at 72 hours (P < 0.001), 96 hours (P < 0.01) and 120 
hours (P <0.01) (Figure 11). These values match with the qualitative findings shown in Panel 
A, Figure 10. Thus, the qualitative trend of enhanced growth for HepG2 cells upon over-
expression of L104R or E126D APEl as compared to cells over-expressing wild-type APEl was 
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statistically quantifiable, providing evidence that the L104R and E126D APEl variants can 
facilitate the growth of HepG2 cells. 
Figure 11. Growth of HepG2 cells transfected with pCMV6-XL5-Wild-typeAPEl (Wildtype 
APEl), pCMV6-XL5-Ll 04R (L104R APEl) or pCMV6-XL5-E126D (E126D APEl) plasmid 
constructs over a six day period. Absorbance values were normalized using the pCMV6-XL5 
(Empty Vector) transfected HepG2 absorbance values at each time point. No sodium arsenite 
was added to the wells prior to incubation. Analysis performed was two way ANOVA with post-
test analysis (n = 3). 
Dot blot analyses were performed to determine whether the exogenous wild-type APEl, 
L104R APEl and E126D APEl proteins were indeed over-expressed in HepG2 cells. The initial 
dot blot performed contained proteins from the empty vector, wild-type APEl HepG2 cells, and 
L104R APEl HepG2 cells. Analysis of blot confirmed that, for both wild-type HepG2 cells and 
L104R APEl HepG2 cells, there was a qualitative, approximately 2-fold increase in intensity of 
detectable APEl protein as compared to empty vector HepG2 cells at all dilutions of the protein 
(Figure 12,25 ng to 1.25 ng). In contrast, there was no difference in P-Actin levels in the 
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samples (Figure 12), demonstrating equal loading of protein samples. The second dot blot 
performed contained proteins isolated from the empty vector, wild-type APEl HepG2 cells, and 
E126D APEl HepG2 cells. Analysis of this blot confirmed over-expression of APEl for wild-
type APEl HepG2 cells in addition to demonstrating an increase in APEl protein levels for the 
E126D APEl HepG2 cells at all loaded concentrations (Figure 13, 50 jag to 1.25 jxg). In addition, 
the timing for the isolation of these proteins (72 hours) matched the first noticeable increase in 
cellular growth upon the over-expression of the population variants (Figure 10A). 
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Figure 12. Dot blot of total cellular protein isolated from pCMV6-XL5-Vector (Empty Vector), 
pCMV6-XL5-Wild-typeAPEl (Wild-type APEl) and pCMV6-XL5-L104R (L104R APEl) 
transfected HepG2 cells. Blots were subjected to incubation with either anti-human APEl or 
anti-human (3-actin monoclonal antibodies. Proteins were collected 72 hours after transfection 
and 0.1 |ig of recombinant human APEl was used as a positive control (n- 1). 
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Figure 13. Dot blot of total cell proteins isolated from pCMV6-XL5-Vector (Empty Vector), 
pCMV6-XL5- Wild-typeAPE 1 (Wild-type APEl) and pCMV6-XL5-E126D (E126D) transfected 
HepG2 cells. Samples were subjected to incubation with either anti-human APEl or anti-human 
P-actin monoclonal antibodies. Proteins were collected 72 hours after transfection (n= 1). 
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3.3.5 Microarray Analysis and Preliminary qRT-PCR 
To investigate whether the expression of L104R and E126D APE1 in HepG2 cells 
affected downstream gene expression as compared to wild-type APE1, mRNA was collected 
from a single biological replicate of (n =1) empty vector HepG2 cells, wild-type APE1 HepG2 
cells, and L104R APE1 HepG2 cells. The total RNA samples were sent to the Hospital for Sick 
Children in Toronto for microarray analysis. Table 8 lists several genes with altered expression 
levels (fold change of 1.6 or above) when comparing between the wild-type APE1 HepG2 cells 
and L104R APE1 HepG2 cells. Two of these genes, highlighted in this table, are implicated in 
cell growth. BCL2-related protein A1 (BCL2A1) was determined to have a fold decrease of 2.26 
in L104R APE1 HepG2 cells as compared to wild-type APE1 HepG2 cells (Table 8). BCL2A1 is 
a regulator of apoptosis in mammalian cells (Zhang et al. 2000). RAS and EF-hand domain 
(RASEF) was shown to have a modest fold increase of 1.75 in L104R HepG2 cells as compared 
to wild-type APE1 HepG2 cells (Table 8). RASEF is a substituent member of the larger RAS 
GTPase superfamily and is implicated in cell proliferation (Shintani et al. 2007). Thus, the 
functions of these two genes, correlated with the initial microarray results, suggests APE1 may 
be regulating the growth of HepG2 cells through these genes, and that the population variants 
have an effect on the ability of APE1 to regulate their cellular mRNA levels. Microarray 
analyses were further investigated using qRT-PCR. In addition to these two genes of interest, a 
third gene (c-myc) was chosen for analyses as c-myc mRNA has been demonstrated to be 
regulated by wild-type APE1 in HeLa cells (Barnes et al. 2009). 
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Table 8. Microarray results with a fold change of greater than 1.6. Three transfection conditions 
were compared - pCMV6-XL5-Vector (Empty Vector), pCMV6-XL5-WildtypeAPEl (Wildtype 
APEl) and pCMV6-XL5-L104R (L104R APEl). Highlighted genes were chosen for subsequent 
qRT-PCR analysis based on their growth related functions in eukaryotic cells. (n = 1). 
Gene Identity 
Solute Carrier Family 6, member 12 (SLC6A12) 
Tensin 1 (TNS1) 
RAS and EF-hand domain (RASEF) 
WD repeat domain 61 (WDR61) 
Phosphoenolpyruvate Carboxykinase 1(PCK1) 
Collagen, type 1, alpha 1 (COL1A1) 
BCI2-related protein A1 (BCL2A1) 
Serologically defined colon cancer antigen 8 
(SDCCAG8) 
Potassium Voltage-gated Channel, subfamily H 
(KCNH1) 
Troponin T type 1 
L104R APEl 
vs Wild-type 
APEl 
L104R APEl 
vs 
EmptyVector 
Wild-type 
APEl vs 
Empty 
Vector 
Fold Increase 
+1.96 -1.91 -3.76 
+1.95 +1.34 
-1.44 
+1.75 +4.12 +2.35 
+1.74 +1.50 -1.15 
+1.71 
-1.01 -1.81 
Fold 
Decrease 
-2.58 -1.67 +1.54 
-2.26 -1.46 +1.58 
-1.78 n/a n/a 
-1.72 -1.16 +1.48 
-1.61 -1.27 +1.26 
To confirm primer specificity and to determine an annealing temperature which would 
produce a single product, melt curves for these two genes were conducted at a range of 
temperatures. At all annealing temperatures tested (52°C to 62°C), both BCLA2 and RASEF 
primers produced a single peak which melted at approximately 86°C (Figure 14A) and 83 °C 
(Figure 14B), respectively. This indicates a single product formation for these primers at these 
temperature ranges. Thus, any of the temperatures tested here can be used for downstream gene 
expression studies as the annealing temperature. 
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Figure 14. Melt curve analyses of the two primer sets used for downstream gene study 
applications. mRNA analyzed was pooled from mRNA isolated from HepG2 cells transfected 
with pCMV6-XL5-Vector, pCMV6-XL5-Wild-typeAPEl and pCMV-XL5-L104R plasmid 
vectors. 
A) BCL2A1 primers; B) RASEF primers 
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As previous experiments in Dr. Lee's lab had established that p-Actin and c-myc primers 
form a single product at an annealing temperature of 60°C (Kim et al. 2009), it was decided to 
proceed with an annealing temperature of 60°C for the subsequent qRT-PCR gene expression 
analyses. For the BCL2A1 gene, preliminary analysis using two biological replicates (n = 2) 
indicate that, when normalized to the P-Actin housekeeping gene, there was no statistical change 
in fold expression when comparing L104R APEl HepG2 cells to that of wild-type APEl HepG2 
cells or empty vector HepG2 cells (Figure 15). In addition, preliminary analysis of the RASEF 
gene indicated no change in expression level when comparing L104R HepG2 cells to that of 
wild-type APEl HepG2 cells or empty vector HepG2 cells for two biological replicates (n = 2) 
(Figure 15). These qRT-PCR results are contradictory with the microarray data, which 
demonstrated a decrease and increase in fold expression for the BCL2A1 and RASEF genes, 
respectively (Table 8). From a single biological replicate (n = 1), it was determined that L104R 
cells had no change in the expression levels of c-myc (Figure 15) as compared to wild-type APEl 
cells. 
68 
CHAPTER 3 - EUKARYOTIC SYSTEMS 
C 
o 
"35 
» 4 K. 
- cfrf /W 
<5* 
V v 
c-myc 
> 1.0 
JS* 
Figure 15. A summary of the quantitative real time polymerase (qRT-PCR) gene expression 
studies comparing the mRNA levels for select genes between the pCMV6-XL5-Vector (Empty 
Vector Control), pCMV6-XL5-Wild-typeAPEl (Wild-type APE1) and pCMV6-XL5-L104R 
(L104R APE1) transfected cells. Gene expression studies were normalized using the p-Actin 
gene. 
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3.4 Discussion 
3.4.1 Effects on Growth Rate of HeLa Cells upon Knockdown of APEl or Over-
expression of APEl Population Variants 
The first step in the eukaryotic cell investigations was to determine if APEl is important 
in the growth of HeLa cells. A change in growth phenotype was expected, as a previous study 
had demonstrated that the knock down of APEl in HeLa cells resulted in an increase in the 
steady state levels of mRNA for a powerful growth related gene, c-myc (Barnes et al. 2009). 
However, the knockdown APEl HeLa cells demonstrated identical, qualitative, growth rate as 
compared to the control HeLa cells (Figure 6, all panels). Such results suggest that endogenous 
APEl does not appear to play an important role in the modulation of growth rate in HeLa cells. 
However, the results from Chapter 2 (observed increase in endoribonuclease activity of the 
L104R and E126D APEl variants in Origami™ (DE3) cells) together with the observations of 
altered RNA cleavage pattern and the RNasin resistant characteristics of these variants in vitro 
(Kim et al. 2012), suggest a gain of function for the L104R and E126D APEl variants. This may 
not be observed in a system where APEl levels are being lowered and may only be observed if 
the variants were over-expressed. Thus, it was deemed logical to conduct experiments to over-
express the L104R and E126D APEl population variants and assess their effect upon the growth 
rates of mammalians cells such as HeLa cells. 
The growth rates of L104R APEl HeLa cells and E126D APEl HeLa cells were 
quantitatively comparable to both wild-type APEl HeLa cells and empty vector HeLa cells 
(Figure 7, all panels). These results did not match the hypothesis which predicted that there 
would be differences in growth rates between the L104R and E126D APEl cells as compared to 
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the wild-type APEl cells. Several reasons could possibly explain for this lack of effect of growth 
of HeLa cells by these APEl variants. One possible explanation involves the plasmid used. The 
particular plasmid constructs used for these experiments were the pCMV5.1-APEl-FLAG 
9 
plasmid constructs and thus all contained a FLAG tag. The FLAG tag may have interfered with 
any effects of the protein folding or substrate binding of the APEl variant proteins. Thus, it was 
decided to use a new vector (PCMV6-XL5) which removed the 3'UTR of APEl and the FLAG 
tag for downstream experiments. In addition, concurrent research in Dr. Lee's lab had initially 
demonstrated that cellular localization of APEl in HepG2 cells may be dependent on cellular 
stress. Specifically, APEl was localizing to P-bodies in the cytoplasm upon stress with sodium 
arsenite. Therefore we hypothesized that any altered mRNA regulation driven by these APEl 
variants may only be observed if APEl were localized to these P-bodies, as P-bodies have been 
shown to be the sites for mRNA degradation (Garneau et al. 2007). Thus, subsequent growth rate 
experiments incorporated sodium arsenite stress. Finally, it may be possible that APEl simply 
does not play any significant role in growth modulation in HeLa cells. Thus, a human hepatoma 
cancer cell line, HepG2, was chosen for subsequent experiments as APEl may possibly play a 
different role in growth modulation for these cells as compared to HeLa cells. 
In summary, neither APEl nor the L104R or E126D variants of APEl play any role in 
the modulation of growth rates in HeLa cells. 
3.4.2 Effects on Growth Rate of HepG2 Cells upon Knockdown of APEl or Over-
expression of APEl Population Variants 
We next examined the effects on growth rate of HepG2 cells upon knock down of APEl. 
Knockdown APEl HepG2 cells showed a qualitative decrease in growth rate as compared to the 
control HepG2 cells for all concentrations of sodium arsenite tested (Figure 8, all panels). These 
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results demonstrated that endogenous APEl plays a role in facilitating the growth of HepG2 
cells. The cause for this decrease in cellular growth rate, however, cannot be determined from 
this experiment. An absence of any of the known functions of APEl (Section 1.3) may 
contribute to this observed decrease in growth rate. However, the results here agree with 
previous observations where APEl has been knocked down: APEl was determined, using a 
proteomics approach, to be important for many functions including cell growth, apoptosis, 
intracellular redox state and mitochondrial function (Vascotto et al. 2009). 
The over-expression of L104R and E126D APEl proteins resulted in a qualitatively 
enhanced growth as compared to that of wild-type APEl HepG2 cells and empty vector HepG2 
cells in the absence or presence of 0.5 mM sodium arsenite (Figure 10, Panels A and B). There 
was less of a qualitative difference between L104R and E126D APEl HepG2 cells compared to 
wild-type APEl HepG2 cells and empty vector HepG2 cells at 1.0 mM sodium arsenite. This 
may be explained by the fact that sodium arsenite was toxic to the cells. There is a visible, 
qualitative decrease in cellular growth for the 1.0 mM sodium arsenite incubation which is in 
contrast to the overall growth of cells in 0 mM sodium arsenite (Figure 10C versus Figure 10A). 
This may interfere with any possible enhancement of growth rate by the population variants for 
this particular incubation condition as the cells were not growing under such toxic conditions. A 
more detailed analysis of the growth rate of HepG2 cells upon expression of the APEl 
population variants was carried out using two-way ANOVA analysis of data pooled from three 
biological replicates. The results were mixed, with statistical significance only being present for 
the L104R APEl HepG2 cells at 120 and 144 hours while the E126D APEl HepG2 cells showed 
statistical significance at 72, 96 and 120 hours (Figure 11). This suggests the increased growth 
effects of expressing these variants were modest. However, there was some evidence indicating 
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the increased growth rate observed in these growth assays may be biologically relevant. First, the 
L104R APE1 HepG2 and E126D APE1 HepG2 cells consistently demonstrated an increase in 
growth rate as compared to wild-type APE1 HepG2 cells over multiple biological replicates. 
Furthermore, there are examples in the literature which stated that changes in growth rate are 
translatable to disease. For example, at 96,120, and 144 hours there was approximately 130-
150% increased growth for the L104R and E126D APE1 HepG2 cells as compared to that of 
wild-type APE1 HepG2 cells (Figure 11). This is comparable to the 150% increase in cell growth 
observed in a study linking over-expression of Vascular Endothelial Growth Factor (VEGF) to 
stimulation of angiogenesis and progression of ovarian cancer (Duyndam et al. 2002). Hence, the 
increase in growth rate observed in these experiments may translate directly into biological 
relevancy in terms of disease pathogenesis. 
For the HepG2 growth assays, sodium arsenite was employed to stress the cells as 
concurrent research in Dr. Lee's lab had shown that APE1 may localize to P-bodies in the 
cytoplasm under stress. Subsequent work has demonstrated that this is not the case and that 
localization of APE1 in HepG2 cells is not affected by sodium arsenite-induced stress. This 
appears to agree with the results obtained here as mild sodium arsenite stress (0.5 mM) did not 
alter the enhanced growth of L104R and E126D APE1 HepG2 cells as compared to no sodium 
arsenite treatment (Figures 10 and 11). These results suggests that sodium arsenite has no direct 
influence on the ribonuclease activity of APE1 or its variants and that APEl and its population 
variants play roles in the growth of HepG2 cells regardless of cellular stress levels. 
The results of the over-expression of L104R and E126D APEl proteins on the growth of 
HepG2 cells (enhanced cell growth for the L104R and E126D APEl HepG2 cells in 0 mM 
sodium arsenite) as well as the demonstration of exogenous mutant APEl protein expression for 
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these population variants (Figure 12; Figure 13), showed a correlation between over-expression 
of the L104R and E126D APEl proteins and enhanced cellular growth of HepG2 cells. Both the 
L104R and E126D APEl variants have exhibited altered RNA cleaving activity as compared to 
the wild-type APEl in vitro (Kim et al. 2012); therefore we elected to investigate if these 
variants have any effect on gene expression through altered ribonuclease activity. 
3.4.3 Comparing the Effects of APEl and its Population Variants on HeLa and 
HepG2 cells 
The knockdown of APEl and over-expression of APEl population variants in HeLa cells 
showed no change in growth rate (Figures 6; Figure 7). In contrast, the knockdown of APEl and 
over-expression of APEl population variants in HepG2 cells showed a decrease and increase in 
growth rates respectively (Figures 8; Figure 10). This poses an interesting question: why are 
growth rate changes observable only for one cell line? It is possible that the observed changes for 
HepG2 cells as compared to that of HeLa cells may be explained by the following facts: 1) 
HepG2 cells are hepatoma cancer cells with advanced differentiation while HeLa cells are 
cervical cancer cells with relatively less differentiation; 2) APEl is known to have distinct 
localization patterns in differing tissue types (Tell et al. 2005). As hepatoma cells are not 
cervical cells, it is possible that APEl and its population variants play a different role in the 
modulation of growth in these two cell lines. In addition, the mechanisms which lead to a cancer 
phenotype in these cells are not identical and thus may have distinct altered signaling pathways. 
Thus, it is possible that APEl and its population variants are only relevant to a molecular growth 
signal present in HepG2 cells but not in HeLa cells. 
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To summarize, it was observed that for HeLa cells, both the knockdown of APE1 and 
over-expression of the population variants resulted in no observable changes in growth. 
However, the knockdown of APE1 and over-expression of the population variants in HepG2 
resulted in an observable decrease and increase in growth rate, respectively. The next set of gene 
expression experiments were performed to potentially determine the molecular mechanism 
whereby APE1 and its population variants caused the observed change in growth of HepG2 cells 
3.4.4 Microarray Analysis and Preliminary qRT-PCR 
This section of the thesis was to determine if the altered RNA cleaving function of the 
L104R and E126D APE1 population variants was responsible for the observed change in growth 
rate of HepG2 cells. To this end, we elected to over-express the APE1 population variant L104R 
in HepG2 cells, harvest mRNA from the L104R APE1 HepG2 cells and subsequently analyze 
harvested mRNA for gene expression changes using microarray analysis. Microarray analysis 
was chosen as it would provide information into the possible molecular targets of this APE1 
population variant. If these targets were determined to be growth related genes, then a strong 
correlation between the APE1 population variants targeting growth related genes and the 
observed increase in growth upon over-expressing the variants in HepG2 cells would be 
demonstrated. The preliminary microarray experiment showed that two growth related genes had 
altered expression levels in L104R APE1 HepG2 cells as compared to that of wild-type APE1 
HepG2 cells. The first was BCL2-related protein A1 (BCL2A1) which is known to act as a 
regulator of apoptosis in mammalian cells (Zhang et al. 2000). The second was RAS and EF-
hand domain (RASEF), which is a substituent member of the larger RAS GTPase superfamily 
and is implicated in cell proliferation (Shintani et al. 2007) (Table 8). This was evidence that the 
initial hypothesis presented for this section was possibly true. However, we recognized some 
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flaws in the present preliminary microarray analysis: 1) the low number of biological repeats (n 
= 1) and 2) microarray data is known to contain background noise. Preliminary qRT-PCR was 
therefore performed in an effort to confirm the results from the microarray analysis. 
In addition to the BCL2A1 and RASEF genes, analysis was carried out for the c-myc 
gene, as c-myc mRNA levels are regulated by APE1 in HeLa cells (Barnes et al. 2009). 
Unfortunately, the results of the qRT-PCR experiments did not match the results obtained from 
the microarray data. From two biological replicates, it was determined that the L104R-expressing 
HepG2 cells did not have any change in the expression levels of BCL2A1 or RASEF mRNA 
(Figure 15). There was also no observable effect on c-myc mRNA levels from a single biological 
replicate (Figure 15). It is possible that the qRT-PCR results are more valid than the microarray 
data as: 1) for the BCL2A1 and RASEF genes, there were two biological replicates performed as 
compared to just one for the microarray analysis study; and 2) the melt curves performed for the 
primers used in this experiment showed specificity of the primers. However, the qRT-PCR 
results may not be reliable either. The protocols for the qRT-PCR in this thesis do not conform to 
the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
guidelines. RNA quality control was performed by comparing the A260/A280 ratio for all RNA 
samples isolated against the established ratio of 1.8-2.0 for pure RNA in lieu of assessing RNA 
integrity by determining the 28S:18S rRNA ratio. Electrophoretic assays to assess for the 
28S:18S rRNA ratio of 2.7:1, the standard for RNA quality assessment, was not performed. In 
addition, only a single reference gene was used for normalization, which is in contrast to the 
MIQE guidelines, which require multiple reference genes. As such, the conclusion drawn in this 
thesis, regarding the gene expression studies, are preliminary results which will need to be 
verified in future studies if this project is to be pursued. 
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We tentatively conclude that the population variant L104R does not specifically regulate 
the expression of the BCL2A1, RASEF or c-myc genes leading to an altered growth phenotype in 
HepG2 cells. However, we do not rule out the possibility of altered mRNA cleaving function of 
this variant as a cause for the change in growth in HepG2 cells. It is entirely possible that there 
are yet unidentified molecular targets of the L104R APE1 variant which is responsible for the 
change in growth via mRNA cleavage. However, we also do not rule out the possibility that the 
change in growth phenotype is due to a deregulation of the other known functions of APE1. 
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Chapter 4 
General Discussion 
4.1 General Overview 
APE1 is a multifunctional protein implicated in many important cellular roles including 
abasic DNA endonuclease cleavage (Evans et al. 2000), acting as a redox factor for many 
growth-related transcription factors (Evans et al. 2000), 3'-5' exonuclease activity for DNA 
(Chou et al. 2000), and endoribonuclease activity against both mRNA and abasic RNA in vitro 
(Barnes et al. 2009; Berquist et al. 2008). APE1 is also known to exist as multiple population 
variants (Section 1.4.1). Previously, some of these population variants have been linked to 
diseases (Section 1.4.2). For instance, the L104R and E126D APE1 variants have been 
previously linked with ALS, and the D148E APE1 variant with various cancers (Section 1.4.2). 
To date, it is still unknown if alterations to of any of the known biochemical functions exhibited 
by the APE1 population variants has any impact at the cellular or organismal level, or whether 
there is a direct influence on susceptibility to disease. Investigation into the ribonuclease activity 
of the L104R and E126D APE1 variants has shown that they demonstrate altered cleavage 
patterns on c-myc CRD mRNA in vitro as compared to that of wild-type APE1 (Table 1). In 
addition, these variants were shown to be resistant to the effects of a powerful RNase inhibitor, 
RNasin (Kim et al. 2012). In contrast, the D148E APE1 variant demonstrated complete 
abrogation of RNA cleaving activity against c-myc CRD mRNA (Kim et al. 2012). 
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4.2 Population Variants of APE1 and Disease 
One of the goals of this investigation was to examine if over-expression of the APE1 
population variants L104R, E126D and D148E would result in a change in phenotype in 
prokaryotic and eukaryotic cells and thus suggest a biochemical correlation between this altered 
phenotype and the diseases they are associated with. 
This thesis demonstrated that the L104R and E126D APE1 variants were cytotoxic to 
Origami™ (DE3) cells while stimulating the growth of HepG2 cells when over-expressed. The 
results here may or may not represent a link between the L104R and E126D variants and ALS. 
ALS is characterized by the degeneration of neuronal cells (Deng et al. 2011). If the results of 
the Origami™ (DE3) cell experiments are taken into account, then it is possible that these 
variants may confer an increase in cytotoxicity to neuronal cells expressing these variants and 
may therefore be involved in the degeneration of the cells. This could be of particular interest as 
a new avenue of investigation into the pathogenesis of ALS. Most contemporary studies 
implicate the causes of ALS to mutations of the SOD1 gene (Al-Chalabi et al. 2000) and 
environmental factors such as head trauma (Piazza et al. 2004). Our results of the mammalian 
cell data is contradictory to the prokaryotic data as the L104R and E126D APE1 variants 
demonstrate either no effect on the growth of HeLa cells or enhanced growth of HepG2 cells 
(Section 3.3.2, Section 3.2.4). 
Since ALS is attributed to the degeneration of cells, the observed enhanced growth 
implies that the above variants may not be responsible for the cell death observed in ALS. 
However, the mammalian data is likely to be a more accurate representation of the situation in 
ALS as ALS is a mammalian disease. Also, it must be considered that the APE1 protein plays 
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distinct roles in differing cell types due to altered localization patterns (Tell et al. 2005). Since 
hepatoma cells are not neuronal cells, it is possible that the expression of these variants in 
neuronal cells may result in cell death as opposed to the enhanced hepatoma cell growth in this 
thesis. In addition, this thesis did not elucidate the biochemical functions of APE1 which are 
responsible for the enhanced cell growth in HepG2 cells. Thus, any of the functions of APE1 
could be implicated in ALS. Therefore, this thesis cannot draw a biochemical link between the 
expression of the L104R and E126D APE1 variants and ALS. To investigate the possible link 
between these variants and the pathogenesis of ALS, future experiments should be performed 
using mammalian neuronal cells and observing phenotypic changes such as cell survivability. If 
changes in growth phenotypes are observed, then gene expression studies should be pursued with 
a focus on selecting appropriate reference genes and controlling RNA quality. 
The D148E APE1 variant has been found to be associated with a large variety of cancers 
(Section 1.4.3). The hypothetical cause for the association of this variant with cancer was 
proposed in this thesis to be disruptions to the ribonuclease activity of APE1. Previously, in vitro 
work had shown a complete loss of RNA cleaving activity for this variant against c-myc CRD 
RNA (Kim et al. 2012). However, the results of this thesis showed that the D148E APE1 variant 
had no effect on cell growth in a prokaryotic system (Section 2.3). This suggests that the 
hypothesis linking deregulation of the endoribonuclease activity of D148E APE1 to cellular 
function does not hold true. Further studies of this variant on mammalian cell systems have not 
been performed. Given that the sensitivity of the prokaryotic system may have been inadequate 
to detect a subtle loss of function of ribonuclease activity of proteins (Section 2.4), it may be 
worthwhile for future studies to assess D148E APE1 in mammalian systems including in 
neuronal cells. This, in itself, may prove to be difficult because the D148E variant is likely 
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responsible for disease in a loss of function aspect. In such a scenario, mammalian cell lines used 
for studies must have an absence of endogenous APEl. This is due to the fact that endogenous 
APEl would mask the effects of a loss of function in the D148E APEl variant. Hence, the most 
appropriate model would be cells that have dominant negative D148E mutations. 
4.3 Concluding Remarks 
Several studies have identified human population variants of APEl. Some of these 
known population variants (L104R, E126D and D148E, in particular) have been correlated with 
diseases such as ALS and cancer. To date, there have been no studies linking the ribonuclease 
activity of the population variants of APEl to disease. The main goals of this MSc thesis were to 
test the hypothesis that these population variants, when expressed in cells, would have an effect 
on phenotype and that this effect could be linked to their ribonuclease activity. The results of the 
Origami™ (DE3) cell experiments indicated that L104R and E126D APEl variants have an 
inhibitory effect on the growth of cells. Also, the experiments suggest that this effect is due to 
ribonuclease activity as these cells have been previously used to demonstrate cytotoxicity, 
through ribonuclease activity, in similar experiments conducted for the ribonucleases RNase A 
and Angiogenin (Smith et al. 2006; Smith et al. 2008). Subsequent expression of the L104R and 
E126D APEl variants in mammalian cells demonstrated a stimulatory effect on the growth of 
HepG2 cells; however, attempts to link this effect to their ribonuclease activity were 
unsuccessful. It is possible that any of the several known functions of APEl and its population 
variants were responsible for this effect. In addition, it was found that APEl and its population 
variants displayed growth effects on HepG2 cells but not on HeLa cells. It is possible that APEl 
plays a different role in various cell types by interacting with multiple unique targets in a given 
cell type. Thus, future studies should include: 1) Investigating the biochemical function(s) of 
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APEl responsible for stimulating growth in HepG2 cells; 2) Investigating the molecular targets 
of APEl (for each biochemical function of APEl) in several different cell lines, particularly in 
neuronal cells. The initial tentative findings here give credence to the hypothesis that there is a 
link between endoribonuclease activity and cellular phenotype for the APEl population variants, 
but future studies will need to be performed to clarify our further understanding of the issue. 
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